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ALLOGRAFT A homograft between allogenic individuals  
 
ANTIBIOTIC STERILIZED 
HOMOGRAFT 
Antibiotic-sterilized valves stored at 4C in nutrient media are considered to be 
non-viable valves. (Yacoub & Kittle, 1970) 
 
 
AUTOLYSIS  In this study autolysis was defined as necrotic cells that showed increased 
eosinophilia attributed in part to loss of the normal basophilia imparted by the 
RNA in the cytoplasm and in part to the increased binding of eosin to 
denatured intracytoplasmic protein It was deemed to be wither present or 
absent in the specimens examined and no grading system was applied.  
 
 
COLD ISCHAEMIC TIME This study defines cold ischaemic time as the ischaemic time period during 
which the intact sheep carcasses were maintained at room temperature of 
230C for 2-3 hours after death, during which time the stomachs were removed, 
before being cooled to 40C. 
 
 
CRITERIA A standard on which a judgment or decision may be based, or a 
characterizing mark or trait. 
 
 
CRYOPRESERVED  
HOMOGRAFTS 
Cryopreserved valves are valves sterilized in antibiotic solution and 
subsequently cryopreserved (O’Brien et al., 1987). 
 
 
DIFFERENTIAL 
SCANNING 
CALORIMETRY 
 
Differential scanning calorimetry (DSC) means the measurement of the change 
of the difference in the heat flow rate to the sample and to a reference sample 
while they are subjected to a controlled temperature program (Höhne, 
Hemminger and Flammersheim, 2003)  
 
ENDOTHELIUM 
 
An epithelium of mesoblastic origin compose of a single layer of thin flattened 
cells that lines internal body cavities (as the serous cavities or the interior of the 
heart). 
 
 
HARVESTING 
 
To remove or extract (as living cells, tissues, or organs) from culture or from a 
living or recently deceased body especially for transplanting. 
 
 
HEAMATOXYLIN AND  
EOSIN STAIN 
 
Probably the most generally useful staining method for tissues, nuclei are 
stained a deep blue-black with haematoxylin, and cytoplasm is stained pink 
after counterstaining with eosin, usually in water (Bancroft and Stevens, 1982). 
 
HERMETICALLY 
 
Being air tight or impervious to air. 
 
 
HOMOGRAFT A graft of tissue from a donor of the same species as the recipient. 
 
 
IMPORTANT DEFINITIONS 
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HOMOGRAFT VIABILITY Viability of a homograft refers to survival of endothelial cells and fibroblasts that 
retain their ability to replicate and regenerate extracellular matrix elements 
(Barili et al., 2007).  Cryopreserved valves are valves sterilized in antibiotic 
solution and subsequently cryopreserved.  They are considered viable if 
cryopreserved within 4 days of procurement (O’Brien et al., 1987).  
 
 
HOMOVITAL  
HOMOGRAFT 
 
These homografts are harvested under sterile conditions, are storage in an 
antibiotic solution at 40C and are not frozen prior to implantation (Yacoub et 
al., 1995).  
 
 
IN VITRO Outside the living body and in an artificial environment. 
 
IN VIVO In the living body of a plant or animal. 
 
 
ISCHAEMIC TIME Ischaemic time is defined as the time interval between donor death and valve 
procurement (Angell et al., 1989; O’Brien et al., 1995).  It is sometimes referred 
to as harvesting time.  This study further qualifies ischaemic time as either cold 
or warm. 
 
 
SCANNING ELECTRON 
MICROSCOPE 
 
An electron microscope in which a beam of focused electrons moves across 
the object with the secondary electrons produced by the object and the 
electrons scattered by the object being collected to form a three-dimensional 
image on a display screen. 
 
 
TENSILE STRENGTH 
 
The greatest longitudinal stress a substance can bear without tearing apart. 
 
 
THERMAL ANALYSIS (TA) TA is based upon the detection of changes in the heat content (enthalpy) or 
the specific heat of a sample with temperature (Ma and Harwalkar, 1991). 
  
  
WARM ISCHAEMIC TIME This study defines warm ischaemic time as the ischaemic time period during 
which the intact sheep carcasses were maintained at room temperature of 
230C for 6 hours after death, before being cooled to 40C.  Stomachs were not 
removed.  
 
 
YOUNG’S MODULUS The modulus of elasticity in tension, also known as Young’s modulus E, is the 
ratio of stress to strain on the loading plane along the loading direction 
(Pukacki, et al., 2000). 
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In hierdie studie word homografts gedefinieer as aorta-, pulmonale- of mitraal- 
weefselkleppe wat geoes word van kloppende hart donors of kadawers (Anastasiadi 
et al., 2004).  Die konsep van homograft lewensvatbaarheid is sentraal in hierdie studie 
sowel as in die kliniese toepassing van homografts in die praktyk.  Lewensvatbaarheid 
word gedefinieer as die oorlewing van endoteelselle in die transplantaat en sluit die 
potensiaal in vir seldeling en -hernuwing van die ekstasellulêre matriks elemente (Barili 
et al., 2007).  O’Brien en medewerkers het die verwantskap tussen lewensvatbaarheid 
en langtermyn uithouvermoë of werkverrigting van homografts reeds in 1987 vasgestel 
(O’Brien et al., 1987). 
 
Verskeie faktore bepaal homograft lewensvatbaarheid, waarvan isgemiese tyd vanaf 
donor dood tot homograft oesting die belangrikste is.  Die meeste homograft banke 
vereis dat die kleppe binne 24 uur vanaf die donor se dood geoes moet word, maar 
hierdie stelling is uiters kontroversieël (Livi et al., 1987).  Die tydsinterval van 24 uur word 
voorgekryf om endoteelselle en fibroblaste se lewensvatbaarheid te verseker wat weer 
‘n daadwerklike impak het op die langtermyn uithouvermoë van die klep (Angell et al., 
1989; O’Brien et al., 1995).  Ondanks die limiet op isgemiese/oestingstyd, verleng talle 
homograft banke die isgemiese tyd weens kriopreservering.  Kleppe wat 
gekriopreserveer word binne 96 uur word beskou as lewensvatbaar (O’ Brien et al., 
1987). 
 
Wheatley en McGregor (1977) het gevind dat vars homografts geoes van honde 
(Homovital) vinniger degenereer en kalsifiseer as die kontroles en het voorgestel dat 
die moontlike rede toegeskryf kan word aan ‘n transplantaat-gasheer immuun reaksie.  
Bogenoemde stelling is teenstrydig met die bevindings van Yacoub en medewerkers, 
 
OPSOMMING 
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en toon dat ‘n oestingstyd minder as 24 uur nie noodwendig langetermyn 
uithouvermoë verseker nie (Yacoub et al., 1995). 
Aangesien die beskikbaarheid van homografts ‘n internasionale probleem is kan die 
verlenging van die voorgekrewe 24 uur oestingtyd voordelig wees vir kadawer-
gebaseerde programme. 
 
Tydens die studie is twee groepe skaap homografts genaamd Groep B en Groep C 
met ‘n kontrole groep (Groep A) vergelyk.  Die skaapharte in Groep A is binne 6 uur 
vanaf dood geoes.  Die karkasse in Groep B is afgekoel na 4ºC en slegs vir 2-3 ure 
blootgestel aan kamertemperatuur (230C).  Groep B vorm gevolglik die koue isgemiese 
groep.  Die karkasse in Groep C is blootgestel aan kamertemperatuur (23ºC) vir ‘n 
periode van 6 uur waarna die karkasse vir ‘n tydperk van 3 dae stadig afgekoel is na 
4ºC.  Groep C vorm dus die warm isgemiese groep. 
 
Tensiele sterkte en differiensiële skandeer kalorimetrie tegnieke het geen verskil in 
weefselsterkte tussen die groepe gedemonstreer nie.  Kriopreservering- en 
sterilisasieprosesse het ook nie bygedra tot ‘n afname in sterkte nie. 
 
Groep B (koue isgemiese groep) het met histologiese ondersoeke geen outolise 
getoon in enige van die kleppe nie.  Die outolise wat wel voorgekom het in die 48 en 
72 uur weefsel van Groep C (warm isgemiese groep) het geen effek op die 
weefselsterkte gehad nie.  Soortgelyk, die vermindering van endoteelselle oor tyd het 
in beide Groep B en C tot en met 72 uur geen invloed getoon op weefselsterkte nie. 
 
Om hierdie redes bleik dit aanvaarbaar te wees om die oestingstyd van 24 uur te 
verleng. 
 
Hierdie resultate sal egter deur verdere proefdierstudies gestaaf moet word aangesien 
in vivo transplantaat-gasheerinteraksie resultate teenstrydig met bogenoemde 
bevindinge kan wees. 
 
In die inplanterings weefsel mag meganismes van degenerasie belangriker wees in die 
in vivo omgewing as bloot net absolute weefselsterkte en -integriteit. 
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In this study, homografts are aortic, pulmonary or mitral tissue allografts harvested from 
either beating heart donors or cadavers (Anastasiadis et al., 2004).  The concept of 
homograft viability is central to both this study and the clinical application of 
homografts in practice.  Viability refers to the survival of endothelial cells in the implant 
and includes the potential for cellular replication and renewal of extracellular matrix 
elements (Barili et al., 2007).  The relationship between viability and long term durability 
or performance of homografts was established by O’Brien and co-workers (O’Brien et 
al., 1987). 
Homograft viability is determined by many factors, the most topical of which is the 
ischaemic time from death of the donor to harvesting of the homograft.  Most 
homograft banks require that valves should be harvested within 24 hours of the donor’s 
death but this requirement is controversial (Livi et al., 1987).  The time interval of 24 
hours seems to ensure viability of endothelial cells and fibroblasts which has an impact 
on long-term valve durability (Angell et al., 1989; O’Brien et al., 1995). Notwithstanding 
the limit on ischaemic/harvesting time, many homograft banks prolong the ischaemic 
time as a result of cryopreservation.  Valves cryopreserved within 96 hours are 
regarded as viable (O’ Brien et al., 1987).  
Wheatley and McGregor (1977) noted that fresh canine homografts (Homovital) 
degenerated and calcified quicker than controls and suggested that this might be 
due to a graft-host immune interaction.  This appears to contradict the findings of 
Yacoub and co-workers, and shows that a harvesting time of less than 24 hours does 
not necessarily guarantee long-term durability (Yacoub et al., 1995). 
As homograft availability is an international problem, extending harvesting time 
beyond 24 hours might benefit cadaver donor based programs. 
 
SUMMARY  
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This study compared two groups of sheep homografts, namely Group B and Group C, 
with a control group of sheep obtained within 6 hours of death, namely Group A.  
Group B carcasses were cooled to 40C and were exposed to room temperature at 
230C for only 2-3 hours.  This was therefore the cold ischaemic group. Group C 
carcasses were kept a room temperature of 230C for 6 hours prior to being cooled 
slowly over a period of 3 days to achieve a temperature of 40C. This was therefore the 
warm ischaemic group.   
Using tensile strength and DSC techniques, no difference in tissue strength could be 
demonstrated between the groups. No reduction in strength could be demonstrated 
as a result of the cryopreservation and sterilisation process 
Histological examination did not show autolysis in any of the valves in Group B (cold 
ischaemic group).  The autolysis observed in the 48 and 72 hour tissue of Group C 
(warm Ischaemic time) was not sufficient to affect tissue strength.  Similarly, a reduction 
of endothelial cells over time in both Group B and Group C did not influence tissue 
strength up to 72 hours. 
It therefore seems to be acceptable to extend harvesting time beyond 24 hours, based 
on these investigations. 
Further animal studies need to be performed to substantiate these results, as the in vivo 
graft host interactions might produce results that are not consistent with these findings. 
Mechanisms of degeneration might be more important in the in vivo situation than 
absolute strength and integrity of the implanted tissue. 
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Use of homografts in cardiac surgery is well established but availability remains the main 
limiting factor in their clinical application. 
 
Homografts are procured from two sources, namely, beating heart donors and 
cadavers.  The factors that limit availability of solid organ transplants from beating heart 
donors apply equally to homografts.  In addition, cadaver homograft procurement is 
limited by the ischaemic time between cardiac arrest and organ harvest.   
 
Current practice regarding allograft harvesting from either source, attempts to confine 
the harvest to within 12 to 24 hours of brain death or cardiac arrest (O’Brien, Johnston, 
Stafford, Gardner, Pohlner, McGiffin, Brosnan, and Duffy, 1988; Livi, Abdulla, Parker, 
Olsen and Ross, 1987).  Although widely accepted, this time limitation has not been 
established scientifically.  Several publications suggest that longer harvest times might 
be acceptable. 
 
In fact there are a number of articles that actually suggest that it would be acceptable 
to extend harvesting times. 
 
Armiger and associates (Arminger, 1995) have suggested that the ischaemic interval 
could be extended up to 30 hours after death.  Messier and colleagues (Messier, 
Domkowski, Aly, Abd-Elfattah, Crescenzo, Wallace and Hopkins, 1992) demonstrated 
high levels of adenine nucleotide pools in cryopreserved allografts after prolonged 
ischaemia.  Kadoba and associates (Kadoba, Arminger, Sawatari and Jonas, 1991) 
confirmed that a 48-hour delay from donor to graft harvest did not have a significant 
effect on conduit function. 
CHAPTER 1 
INTRODUCTION 
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Periods of ischaemia are unavoidable during homograft processing.  Such periods 
occur between cessation of the donor heartbeat and harvesting (cadaveric recovery) 
and during the preservation in tissue storage solution and the sterilization process that 
follows.  A period of up to 4 days between death and final cryopreservation is 
commensurate with homograft viability (O’Brien, Stafford, Gardner, Pohlner and 
McGiffin, 1987).  Viability refers to the survival of endothelial cells in the implant and 
includes the potential for cellular replication and renewal of extracellular matrix 
elements (Barili, Dainese, Cheema, Dell’Antonio, Topkara, Rossoni, Guarino, Micheli, 
Doglioni, Biglioli and Polvani, 2007).  The circumstances of death, post-mortem 
temperature changes, Body Mass Index’s (BMI’s) of the donors and immediate changes 
in tissue quality and its impact on objective tissue deterioration over time, have been 
insufficiently studied.  Standardization of time related harvesting protocols which are 
currently internationally accepted, are based on observational studies rather than 
controlled scientific data such as that of O’Brien et al., (1987). 
 
The fact that acceptable long-term results were obtained in the fresh albumin stored 
homografts, stored at 4°C for up to 90 days (Goffin, De Gouveia, Szombathelyi, 
Toussaint and Gruys, 1997), implies that ischaemic time between death, harvesting and 
implantation is well tolerated.  The time after death, before harvesting, forms a fraction 
of the time in this setting.  What needs to be addressed is what happens to the 
homograft tissue in the body after death before harvesting, and how this impacts on 
homograft performance. 
 
Most heart valve banks worldwide require that donor tissue be harvested up to and less 
than 24 hours after death.  This can limit the availability of valves dramatically in 
cadaver donors requiring medico-legal autopsies, an important donor pool in some 
countries like South Africa, because of time and logistical implications. The mean time 
from death to harvesting in Bloemfontein is 33 hours. 
 
Ideally, objective criteria must be developed in order to predict the quality of the 
homograft tissue before processing and implantation. This will enable the surgeon to 
apply additional selection criteria other than time, to select homografts for processing 
(cryopreservation) with a greater degree of confidence as to their ultimate in vivo 
performance. 
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The purpose of the study was: 
 
1. To evaluate tissue degeneration post mortem in a sheep model in a controlled 
environment using 24 h, 48 h and 72 h groups, using objective criteria including 
histology (H&E) Scanning Electron Microscopy (SEM), Tensile Strength and 
Differential Scanning Calorimetry (thermal denaturation temperature)(Td). 
 
2. To evaluate the impact of different ischaemic temperatures upon tissue 
degeneration between “warm” and “cold” ischaemic time groups in the in vitro 
sheep homograft model. 
 
3. An attempt to establish a relationship between the quality of tissue as assessed 
histologically (e.g. signs of autolysis) and presence of endothelium (SEM) on the 
one hand, and tissue strength, (tensile strength and DSC) on the other.  
 
4. An attempt was made to establish whether a relationship existed between the 
aorta, pulmonary wall and mitral valve, aorta and pulmonary valve leaflets, in 
order to predict quality of implanted tissue by using non implanted tissue as 
reference tissue. 
 
Hopefully this study would provide objective data (post cryopreservation) on sheep 
homografts that would demonstrate the quality, or the lack thereof, of tissue harvested 
up to 72 hours after death using the described methods.  
 
Lu and co-workers in 1998 concluded that a 30 – 60 hour delay did not have significant 
metabolic effects on the cardiac leaflets (Lu, Chang, Hsu, Hwang, Chong, Wu, Yang 
and Hsing-Wen, 1998).  This suggests that it may be possible to safely extend the 
permissible ischaemic periods after organ harvest, which could have an important 
impact on homgraft availability in South Africa. 
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2.1 BACKGROUND 
 
In this study, the term homograft refers to aortic, pulmonary or mitral tissue 
allografts harvested from beating heart donors or cadavers (Anastasiadis, 
Kambouroglou and Spanos, 2004). 
 
The history of using homologous cardiac valves and great vessel valve-
containing conduits dates back more than 30 years.  Animal studies reported by 
Lam et al., (1952) formed the basis for other investigators to use the concept in a 
different and more successful way (Lam, Aram and Mennell, 1952).  In 1956, 
Gordon Murray’s pioneering work in Toronto demonstrated that homologous 
aortic valve segments could be transplanted into not only the descending aorta 
but also the mitral position (Murray, 1956).  After experimenting with this 
technique in dogs, Murray successfully applied the concept in two patients with 
aortic regurgitation and later in one with mitral valve disease. 
 
It was not until 1962, however, that the aortic homograft (Figure 2.1.1) was 
inserted in the native or sub coronary position of the heart (Ross, 1962).  This was 
made possible by the development of the heart-lung machine, which opened 
the door for all types of intra-cardiac corrective and palliative procedures.  With 
technical help from Gunning and Duran, Donald Ross performed this procedure 
for the first time at Guy’s Hospital in London on July 24, 1962 (Ross, 1962).  Barratt-
Boyes at the Green Lane Hospital in New Zealand independently developed the 
same concept for sub-coronary replacement of the aortic valve with a 
CHAPTER 2 
LITERATURE REVIEW 
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homograft aortic valve and began performing it clinically in August 1962 (Barret-
Boyes, 1965). 
 
In the absence of mechanical alternatives, it is understandable that these early 
pioneers turned to the homograft valve.  They felt it would be difficult to improve 
on the efficient design characteristics of the human aortic valve (Ross, 1962).  In 
the normal heart it provides no obstructive gradient at rest or with exercise and 
provides central blood flow with minimal turbulence during left ventricular 
ejection.  It also has an absolutely regurgitation-free natural closure mechanism 
due to the design of the sinuses of Valsalva. 
 
 
 Figure 2.1.1 Aortic Homograft Conduit 
 
The technical difficulty of inserting a competent homograft valve was a greater 
surgical challenge than the insertion of a corresponding mechanical prosthetic 
device.  However, within 3.5 years of experience, Ross had implanted 110 aortic 
homografts with progressively decreasing operative risk and improved technical 
performance (Ross, 1962). 
 
At this point in time the aortic homograft was well established due to its low 
gradient, low risk of thromboembolic events, high resistance to endocarditis and 
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acceptable long-term results when compared with alternative bioprosthetic and 
mechanical valves (Barret-Boyes, Roche, Subramanian, Pemberton and 
Whitlock, 1987; O’Brien, Stafford, Gardner, Pohlner, McGiffin, Johnston, Brosnan 
and Duffy, 1987). 
 
Prompted by the limited availability of donor valves, emphasis was placed on 
pulmonary valve homografts (Figure 2.1.2) as aortic valve substitutes in the early 
1990’s (Koolbergen, Hazekamp, de Heer, van Hoorn, Huysmans, Bruijn and Dion, 
2002).  In vitro biomechanical testing supported this argument and showed that 
the pulmonary valve was capable of withstanding the higher pressure of the 
systemic circulation.  It was also reported that the pulmonary homograft wall 
tissue calcified less than the aortic homograft wall tissue, and the pulmonary 
autograft in the aortic position had excellent long term results.  However, acute 
cusp rupture of the pulmonary homograft implanted in the aortic position was 
reported in 1994 (Koolbergen et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.1.2 Aortic and Pulmonary Homograft Conduits (adapted from Verghese, Padmaja, 
Sindhu, Elizabeth, Lesley and Cherian, 2004). 
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2.2 PROCUREMENT OF HOMOGRAFTS 
 
2.2.1 Donors 
  
Homografts can be harvested from non-beating hearts or beating hearts: 
 
2.2.1.1 Non-beating heart donors 
 
Historically, fresh cadavers have been the source of various types of 
human tissues.  The European practice of obtaining tissues from the 
hospital morgue is well known.  Non-beating heart donors are deceased 
hospital patients or forensic cases.  
 
The postmortem delay must be less than 24 hours with an exposed warm 
ischaemic time of less than 6 hours (Goffin, Grandmougin and Van Hoeck, 
1996). 
 
 2.2.1.2 Beating heart donors 
 
The maximum delay after brain death must not exceed 18 hours with no 
warm ischaemic time.  The operating room is currently the preferred site of 
harvesting, because it maximizes the sterility of tissue procurement. 
 
2.2.2 Inclusion and Exclusion Criteria for Homograft Donation 
 
 2.2.2.1 Donor screening 
 
Donor screening is an important element of the procurement process 
(O’Brien et al., 1987).  Any history or laboratory evidence of 
communicable disease makes transplantation of the donor’s organs or 
tissues inadvisable.  Heart valves obtained from donors of approximately 
55 years of age or less are generally suitable, provided there is no history 
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of diabetes, hyperlipidemia, or hypertension.  Donors following cardiac or 
great vessel trauma or those with severe mediastinal adhesions may be 
excluded as potential donors. 
 
Laboratory data includes serologic tests for syphilis, hepatitis, and human 
immunodeficiency virus (HIV).  Blood cultures and autopsy findings are 
obtained, and blood typing is also performed.  Full term infants and young 
children are the only suitable donors of small diameter grafts needed for 
cardiac reconstructive surgery in infants.   
 
Other exclusion criteria include clinical evidence of Marfan’s syndrome, 
history of collagen or immune complex diseases, dementia or 
neurological degenerative disease of any form, irradiation to the thorax 
and a history of consuming toxic substances. 
 
2.2.2.2 Human Decomposition after Death 
 
Human decomposition or autolysis begins approximately 4 minutes after 
death.  As cells of the body are deprived of oxygen, blood carbon 
dioxide levels will increase which will decrease pH as waste accumulates 
which causes cell poisoning.  Simultaneously, cellular enzymes (lipases, 
proteases, amylases, etc) begin to dissolve cells from the inside out, 
eventually causing them to rupture, releasing nutrient-rich fluids. 
 
Autolysis usually does not become visually apparent for a few days.  
Meanwhile, as the body acclimates to ambient temperature (algor 
mortis), blood settles in the body causing skin discoloration (livor mortis) 
and cellular cytoplasm gells due to increased acidity (rigor mortis).  After 
enough cells have ruptured the process of putrefaction begins (Vass, 
2001). 
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Putrefaction is the destruction of soft tissue by micro-organisms (bacteria, 
fungi and protozoa) and results in the catabolism of tissue into gases, 
liquids and simple molecules.  Although decomposition is a complicated 
process, it is primarily dependent on temperature and to a lesser extend 
moisture.  The rate of decay can be affected by variables of different 
natures concerning the corpse itself (intrinsic factors) and the external 
environment.  Among the intrinsic factors are age (slower in fetuses and 
newborns), constitution (obese corpses decompose more rapidly due to 
the greater amount of liquid in the tissues whose succulence favours the 
development and dissemination of bacteria), cause of death (early and 
rapid putrefaction occurs in wasted away persons, those suffering from 
septic infections, in death from asphyxia because blood fluidity promoting 
bacterial diffusion), integrity of corpse (cuts in the skin are an easy way in 
for external bacteria and Diptera).  Among the extrinsic factors, the most 
important is temperature (temperatures ranging between 25 and 35°C 
are optimal for bacterial development) followed by ventilation and 
humidity.  Clothing can slow down postmortem body cooling and favour 
the onset of the putrefaction process (Henssge, Knight, Krompecher, 
Madea and Nokes, 1995).  
 
2.2.2.3 Warm Ischaemic Time (WIT) 
 
Homograft durability has clinically been related to cellular “viability” 
(Angell, Oury, Lamberti and Koziol, 1989; O’Brien, Stafford, Gardner, 1995).  
Warm ischaemic time or the harvesting interval, is defined as the time it 
takes from death to the actual harvesting of the valve and has been 
recognized as the main determinant of cell survival.  However, there is a 
great controversy regarding an acceptable warm ischaemic period.  For 
cardiac valves the graft harvesting time varies from 2 to 72 hours.  Some 
investigators believe that the use of valves harvested more than 24 hours 
after death is unacceptable because the valve leaflet cells are non-
viable. 
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Endothelial cell viability plays a role in homograft valve durability but the 
extent is unclear.  It has been suggested that endothelial cell retention 
might be a factor for homograft valve resistance to the degeneration 
process.  The resistance of endothelial cells to warm ischaemic time (WIT) 
is still debatable, but vascular endothelium is thought to have a lower 
resistance to ischaemic injury.  Yankah and Hertzer (1987) reported a 24% 
survival rate of endothelium after a 2 hour exposure to room temperature, 
while other experiments suggested the destruction of the endothelial layer 
between 24 to 48 hours postmortem.  A study performed on rat models 
indicated that the endothelium was viable for at least 40 hours 
postmortem (Yankah and Hertzer, 1987). 
 
Current practice regarding the harvesting and cryopreservation of 
homograft valves are based on the premise that the cell matrix (the 
smooth muscle cells and fibroblasts) viability enhances valve durability.  
Recently, a more precise definition of fibroblast ischaemic damage was 
presented (Crescenzo, Hilbert, Barrik, Corcoran, St. Louis, Messier, Ferrans, 
Wallace and Hopkins, 1992).  It was demonstrated that an ischaemic 
time-dependent progression in fibroblast damage, in the first 12 hours of 
warm ischaemic time, reversible damage predominated, while a marked 
increase of irreversible damage after 12 hours was reported.  Fibroblast 
response to warm ischaemic times, correlate well with the morphometric 
findings, (St Louis, Corcoran, Rajan, Conte, Wolfinbarger, Hu, Wang, 
Hilbert, Analouei, and Hopkins, 1991) in functional studies, and also the 
mechanisms of damage due to the depletion of high-energy phosphate 
intermediates (Messier et al., 1992). 
 
Time spent on sterilization and processing before cryopreservation differs 
widely between institutions.  Sterilization and incubation methods vary 
from 6 hours to 48 hours at 37 ºC to longer periods (48-72 hours) at 4 ºC.  
This extends the warm ischaemic time for different reasons and times.  
Clearly the component between death and harvesting and between 
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harvesting and cryopreservation are two distinct times and its separate 
effects should be separately addressed, although it has never been seen 
this way. Limited data is available concerning the effects of warm 
ischaemic times on valvular grafts.  In order to secure a stable clinical 
supply of allografts, the time limit of exposure to warm ischaemia must be 
clarified (St Louis et al., 1991). 
 
2.3 AVAILIBILITY OF HOMOGRAFTS 
 
A more significant problem is the availability of homografts.  Logistically, it is rare 
that a patient with just the right size valve dies at just the right time to make that 
valve available to the patient who needs it the following morning.  The 
technique of cryopreservation has been most important in providing banks for 
cardiac valves. 
 
The availability of aortic homografts is limited and therefore their use is restricted 
to special indications.  Prompted by the limited availability of donor valves, 
emphasis was placed on pulmonary valve homografts as aortic valve substitutes 
in the early 1990’s (Koolbergen et al., 2002).  An argument to support this policy 
was that in vitro biomechanical testing had shown that the pulmonary valve is 
able to withstand the higher pressures in the systemic circulation (Groczynski, 
Trenker, Anisimowicz, Gutkowski, Drapella, Kwiatkowska and Dobke, 1982).  In 
addition, calcification of the pulmonary homograft wall had been reported to 
be less than that of the aortic homograft wall tissue (Allen, Shoji, Fujimura, 
Gordon, Thomas, Brockbank and Disteche, 1991).  Therefore, availability was 
addressed by the procurement of both aortic and pulmonary homografts. 
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2.3.1 Factors that Influence the Amount of Available Homografts 
 
2.3.1.1 Ethical Considerations 
 
Advances in medical technology and practices and the success of 
organ transplantation over the past two decades vastly increased the 
demand for organ donors.  However, a worldwide shortage of donor 
organs is experienced by the health care community and the organ 
procurement organizations.  The most problematic factor is the non-
consent provided by families of suitable potential donors (West and Burr, 
2002). 
 
In the South African scenario, consent is not the only hurdle to overcome; 
strong cultural beliefs limit the amount of potential donors dramatically.  
Cultural beliefs are part of people’s values and may be difficult to 
change. 
 
  2.3.1.2 Microbial Contamination 
 
The allograft heart valve is harvested from a brain-dead or postmortem 
donor, processed in an antimicrobial disinfection solution, cryopreserved, 
and stored until required.  Tissue samples obtained for sterility testing are 
cultured for bacteria and fungi at multiple stages during harvesting and 
processing to rule out microbial contamination of the valve (Wain, 
Pearce, Riddell and Ross, 1977). 
 
Allograft heart valves are more prone to microbial contamination than 
fungal contamination due to unsterile harvesting conditions.  Common 
contaminants found before disinfection, consist of gastrointestinal and skin 
flora, including coliforms, viridans group streptococci, Staphylococcus 
aureus, Staphylococcus epidermidis, and Bacillus species.  Pathogens that 
cause early onset of allograft valve endocarditis include Staphylococcus 
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and Streptococcus species (Gall, Smith, Willmette, Wong and O’Brien, 
1995).  Sources of contamination of a valve allograft include the donor, 
the environment during harvesting and processing, and the operating 
room during implantation. 
 
Varying contamination rates measured during allograft heart valve 
harvesting and processing may reflect different methods of harvesting, 
disinfection, and cryopreservation.  In order to meet the demand for valve 
allografts, supply has been increased through harvest from deceased in 
addition to brain-dead donors.  Microbial contamination is quite common 
at the time of harvesting, particularly in postmortem procurement.  In one 
series 54% of postmortem heart valves retrieved in open mortuary areas 
were contaminated at collection; 31 of 642 valves were discarded 
because of contamination, the minority of contaminating organisms were 
fungal based (6 of 642) (Gall, Smith, Willmette and O’Brien, 1998). 
 
Disinfection of valve allografts through the use of various antimicrobial 
combinations was first described in the 1960s (Gall et al., 1995).  Since that 
time, antimicrobial agents used for disinfection have been further 
modified to improve efficacy and valve viability, increasing the supply of 
usable allografts. 
 
The establishment of “homograft banks” eventually addressed the 
problem of availability.  Although valve banks employ different 
disinfection protocols, it is obvious that a valve yielding positive microbial 
culture post sterilization will be discarded and considered unfit for 
transplantation. 
 
2.3.1.3 Histocompatibility (HLA) 
 
Histocompatibility control or homograft cross-matching is currently 
performed in certain centers to avoid graft degeneration caused by the 
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recipient’s immune response.  However, this appears to be unnecessary 
as valvular endothelium lacks expression of carbohydrate antigens 
(Kadner et al., 2001). 
 
The effect of histocompatibility on the long term results of homografts is 
the subject of ongoing research (Bechtel, Bartlets, Schmidtke, Skibba, 
Müller-Steinhardt, Klüter and Siever, 2001). 
 
2.4 PRESERVATION OF HOMOGRAFTS 
 
The availability of homografts was addressed by shifting the emphasis to the 
improvement and development of more advanced preservation techniques. 
 
 2.4.1 Classification of Homografts 
 
Homograft valves are classified as homovital, antibiotic sterilized and 
cryopreserved valves based upon the method of preservation: 
 
2.4.1.1 Homovital Valves 
 
Homovital valves are untreated valves, harvested under sterile conditions 
usually from the recipient at the time of the heart transplantation and 
kept in nutrient media they are considered viable if implanted within 3 
days (Yacoub, Rasmi, Sundt, Lund, Boyland, Radley-Smith, Khaghani and 
Mitchell, 1995). 
 
The early sterilization and storage methods included the use of 
chlorhexidine, formaldehyde, propiolactone, ethylene oxide and  
γ -irradiation. 
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2.4.1.2 Antibiotic Sterilized Valves 
 
Antibiotic-sterilized valves stored at 4° C in nutrient media are considered 
to be non-viable valves. 
 
Since 1968 homograft valves have been sterilized using antibiotics and 
stored in culture media at 4° C (Yacoub and Kittle, 1970).  The short- and 
mid-term clinical results with antibiotic-sterilized valves were superior to 
those with chemical sterilization and similar to those with untreated fresh 
homograft valves (Barret-Boyes, Roche and Whitlock, 1977).  Antibiotic-
sterilized valves stored at 4° C are considered to have a finite storage time 
of about 6-8 weeks. 
 
These grafts were all nonviable and had a high risk of cusp rupture and 
valve calcification and an unpredictable development of graft failure 
(Beach, Bowman, Kaiser, Parodi and Malm, 1972). 
 
2.4.1.3 Cryopreserved Valves 
 
Cryopreserved valves are valves sterilized in antibiotic solution and 
subsequently cryopreserved.  They are considered viable if 
cryopreserved within 4 days of procurement (O’Brien et al., 1987). 
 
The development of cryopreservation led to the resurgence of 
homografts.  This allowed for the procurement of quality tissue for 
implantation both in distance and time, and allowed the development 
of so-called “valve Banks”. 
 
The basic concepts of homograft valve cryopreservation were initially 
reported by Ross in 1972 who freeze-dried, or rapidly froze sheep valves in 
dimethylsulfoxide (DMSO) (Savage, Jones, Thompson and Ross, 1972).  
Mark O’Brien in Brisbane, Australia, developed a standardized technique 
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of valve cryopreservation involving controlled-rate freezing after short-
term antibiotic sterilization (O’Brien et al., 1987).  This made the concept 
of long-term storage of viable heart valves possible and available on a 
widespread basis.  The O’Brien technique was imported by Kirklin in 
Birmingham in 1981 (Kirklin, Smith, Novick, Naftel, Kirklin, Pacifico, Nanda, 
Helmcke and Bourge, 1993) and was further developed by a commercial 
cryopreservation center for the processing and nationwide redistribution 
of homograft cardiac valves.  However, the development of valve 
storage by cryopreservation in liquid nitrogen in the 1970s has significantly 
extended storage time, probably indefinitely (Mermet, Buch and Angell, 
1970).  This made the availability of high-quality homograft tissue a reality. 
 
Cryopreservation is the standard preservation technique currently in use. 
 
2.4.2 The Effects of Preservation Techniques on Homograft Viability and 
Integrity 
 
While major centers were working on the technical problems of 
homograft aortic valve replacement, it became apparent that 
preservation techniques were not only destroying the viability and 
cellular architecture of the homograft valve but they were also 
substantially altering their matrix and ground substance.  Valve durability 
may be related to the presence of viable graft cells or the structural 
integrity of the collagen and elastic matrix (or both), although this issue 
remains extremely controversial (Gonzalez_Lavin, Spotnitz, Mackenzie, 
Gu, Gadi, Gullo, Boyd and Graf, 1990). 
 
Some authors (McNally and Brockbank, 1992) have suggested that 
several tissue processing variables such as ischaemic time, antibiotic 
disinfection, cryopreservation, and thawing methods all affect viability.  
In spite of improved cryopreservation techniques, significant morphologic 
and metabolic changes may lead to implant failure. 
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Viability of the homograft valve is determined by the viability of 
fibroblasts present in the valve leaflets (O’Brien et al., 1987) and there is 
evidence that long-term durability may be determined, at least partially 
by viability of the valve at the time of implantation (McGiffin, O’Brien, 
Stafford, Gardner and Pohlner, 1988).  The criteria for valve viability is 
when fibroblasts could be cultured from the leaflet, when living cells were 
seen histologically, and when the whole valve had a glucose utilization 
exceeding 16mg/dl/24 hour (O’Brien et al., 1987). 
 
Cryopreserved homografts have shown favorable clinical results after 
implantation that seems to be attributable to viable fibroblasts present in 
the valve (O’Brien et al., 1988).  Viable fibroblasts synthesize the main 
components of the extracellular matrix: collagen, elastin, reticulin, and 
mucopolysaccharides; therefore the longevity of the implantation is likely 
to be related to the viability of fibroblasts in the implanted valve (Van der 
Kamp and Nauta, 1979). 
 
However, cryopreservation can damage cells and thereby can affect 
cell viability.  The process of cryopreservation is relatively complex 
involving many variables; harvesting (warm and cold ischaemic times), 
sterilization (antibiotics, including antifungal media for 24 hours), freezing 
(fluid shifts and ice crystal formation), storage and thawing.  Each of 
these steps involves the potential for cellular injury (Gall et al., 1995). 
 
There is a great deal of controversy regarding the presence of viable 
fibroblasts within the allograft leaflet matrix at the time of implantation.  
Evidence suggests that cryopreserved valves viable at the time of 
cryopreservation have a much lower level of structural deterioration than 
nonviable valves.  Yacoub et al., (1995) also observed that valves with a 
larger degree of fibroblast viability had an improved long-term durability. 
Cellular viability is also affected by multiple combinations of antibiotics 
with or without fungal drugs to obtain a sterile graft for implantation.  It 
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has been observed that cryopreservation after a period of antibiotic 
sterilization significantly reduces viability and the use of antifungal drugs 
reduces this viability even further (Goffin et al., 1996). 
 
On the other hand Wheatley and McGregor (1977), importantly showed 
that there is a pronounced immunological response to homovital valves, 
suggesting that intact viable endothelium evokes a normal host-graft 
reaction that leads to immune mediated early deterioration of allografts.  
The results of this study indicated that pre-implantation viability results in 
gross valve distortion and shrinkage with consequent loss of function.  
Nonviable valves, in contrast, showed minimal alteration in valve 
dimensions with retention of normal function.  These findings have 
considerable implications in the preparation and clinical use of allograft 
heart valves (Wheatley and McGregor, 1977). 
 
This finding suggests that a certain degree of endothelial destruction 
might be beneficial for graft survival.  These findings also suggested that 
very fresh homovital valves might require immunosuppressant therapy to 
enhance long-term graft survival. 
 
Wheatley’s findings suggest that there is a degree of autolysis or process 
related damage to endothelium, that benefits graft survival. Presumably 
this correlates with retention of the tissue scaffold of the graft (Wheatley 
and McGregor, 1977).  
 
Cryopreservation remains the most commonly used method for valvular 
preservation and storage. 
 
2.4.3 Methods for Evaluating Homograft Viability and Integrity 
 
Homografts can be examined for their viability (with dye exclusion 
method during light microscopy), for their ultra structural morphology (by 
C h a p t e r  2  –  L i t e r a t u r e  R e v i e w  P a g e  | 19 
  
transmission electron microscopy), for their cellular detail (by hematoxylin 
and eosin staining) and for their endothelial function (with 
pharmacological analysis) (Pompilio, Polvani, Antona, Rossoni, Guarino, 
Porqueddu, Buche, Biglioli and Sala, 1996).  However the two most widely 
used techniques are transmission electron microscopy and the 
hematoxylin and eosin stain. 
 
2.4.3.1 Electron Microscopy (EM) 
 
Electron microscopy is used to assess the extent of cellular damage.  A 
set of criteria proposed by Crescenzo and colleagues are followed to 
evaluate cellular damage: that is cytoplasmic oedema, dilation of 
endoplasmic reticulum, mitochondrial swelling, (as signs of reversible 
cellular injury), and mitochondrial flocculent densities, karyolysis, and 
disrupted plasma membrane (signs of irreversible cell injury) (Crezscenzo 
et al., 1992). 
 
2.4.3.2 Scanning Electron Microscopy (SEM) 
 
Scanning electron microscopy (SEM) proved to be a valuable tool for 
investigating biological surfaces.  In the vascular wall and the cardiac 
valves, it is especially suitable for detection of fine changes in endothelial 
covering and underlying layers (Figure 2.4.1 Heart valve X140 
magnification; Figure 2.4.2 heart valve x1200 magnification) (Feng, van 
Hove, Mohan, Walter and Herman, 1993; Hammon, O’Sullivan, Oury and 
Fosburg, 1974; Páral, Ferko, Mĕřička, 2000). 
 
Both sides of the pulmonary and aorta valve leaflets are covered by 
endothelial cells, arranged in the circumference of the valve 
mechanism.  The pattern of the endothelial cells and the arrangement of 
the collagen fibers may serve as an indicator for the organizing leaflet 
structure.  Scanning electron microscopy is regarded as a valuable tool 
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to detect changes in the endothelial covering, basement membrane 
covering and supporting collagen layers of the valve leaflets and arterial 
wall (Figure 2.4.3)(Krs, Burkert, Slizova, Kobylka and Spatenka, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.1 Aortic valve leaflet (x140 magnification) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.2 Aortic valve leaflet (x1200 magnification) 
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 Figure 2.4.3 Criteria Scanning Electron Microscopy (adapted from Krs et al., 2006) 
 
CATEGORY VI
Morphological intact endothelium – putative physiological changes are
not reflected in the superficial morphology of endothelial cells
CATEGORY V
Confluent endothelium with structural inhomogenity – irregularities in the
form of individual cells and changes of their membranes are detectable.
CATEGORY IV
Disruption of intercellular contacts – continuity of endothelial coverage is
lost, endotheliocytes shrink while still adhering to the basal membrane.
CATEGORY III
Separation of endothelial cells – endotheliocytes separate from the basal
lamina. Initially they protrude by their intercellular edges into the lumen;
later it is possible to observe patchy stripping of endothelium.
CATEGORY II
Complete loss of endothelium – denudation of the endothelial covering
with the basal lamina exposed.
CATEGORY I
Damage of subendothelial layers – the valvular surface is covered only
with remnants of basal membrane, the fiber structure of the lamina
fibrosa and the lamina ventricularis may be dissolved.
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2.4.3.3 Haematoxylin and Eosin Staining (H&E) 
 
The haematoxylin and eosin stain is probably the most widely used 
histological stain. It is essential for recognizing various types and 
morphologic changes that form the basis of contemporary cancer 
diagnosis.  Its popularity is based in its ability to demonstrate clearly an 
enormous number of different tissue structures like cytoplasmic, nuclei 
and extracellular matrix features (Gamble, 2008). 
 
Haematoxylin has a deep blue colour and stains nucleic acids where 
eosin stains proteins non-specifically (Figure 2.4.4).  In biological tissue the 
colour indicators for specific structures are: 
  
Table 2.4.1 Haematoxylin and Eosin staining characteristics (Gamble, 
2008) 
 
Tissue structure 
 
 
H&E staining colours 
Nuclei Blue 
Cytoplasm Varying degrees of pink 
Extracellular matrix Varying degrees of pink 
 
Considerable detail is revealed in well-fixed cells.  The nuclei show 
varying degrees of cell-type- and cancer-type specific patterns 
(heterochromatin consideration) that are diagnostically very significant.  
Nucleoli are stained by eosin.  When there is an abundance of 
polyribosomes the cytoplasm will have a distinct blue cast.   
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Figure 2.4.4 Aortic valve leaflet (H&E stained – 40x magnification) 
 
Therefore, the stain discloses abundant structural information, with 
specific functional implications.  On the other hand a limitation of 
Hematoxylin staining is that it is incompatible with immunofluorescence 
(Gamble, 2008). 
 
2.4.3.4 Glucose Utilization Test 
 
According to O’ Brien (1987) the viability can be assessed with a glucose 
utilization test.  A homograft is considered viable when the whole valve 
has a glucose utilization exceeding 16mg/24 hour. 
 
2.4.3.5 Tensile strength 
 
One of the most common testing methods called tensile testing is used to 
determine the behaviour of a sample while an axial stretching load is 
applied.  These types of tests may be performed under ambient or 
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controlled (heating and cooling) conditions to determine the tensile 
properties of a material. 
 
Tensile testing is performed on a variety of materials which includes 
industrial products like plastics, papers, rubbers etc and for the 
determination of tissue strength in the medical field (Akhyari, Fedak, 
Weisel, Lee, Verma, Mickle and Li, 2002).  Tensile testing is used to 
determine the maximum load (tensile strength) that material or a 
product can withstand.  Tensile testing may be based on a load value or 
elongation value (Figure 2.4.5). 
 
Mechanical properties of tissue can be investigated by using a tensile 
testing machine, where the tissue sample is fixed between clamps at 
both ends. The fixed tissue is gradually pulled apart (0.1mm/s) by 
applying constant pressure on the two ends, and the data recorded on 
a personal computer (Thubrikar, Deck, Aouad and Nolan, 1983). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.5 Tensile strength curve (Load (N) / Time (minutes) 
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2.4.3.5.1 Tensile stress and strain 
 
By measuring the average force exerted per unit area, stress can be 
measured.  The total internal forces acting in a body, as a reaction to 
an external applied force gives a measurement for stress.  The unit for 
stress is Pascal (Pa) which translates to one Newton (N) force applied 
per square meter (m2) area (Sasaki and Odajima, 1996). 
 
The deformation of a material by the action of stress is called strain.  
Strain is expressed as the change in shape or size of an object, by 
measuring the difference between two points, one in the unchanged 
state before deformation and one in the changed state after 
deformation gives us a measure of strain (Figure 2.4.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.6 Stress-Strain curve 
 
2.4.3.5.2 Young’s Modulus 
 
Modulus of elasticity (or Young's Modulus) is a measurement of the rate 
of change of strain as a function of stress (Figure 2.4.7).  It represents the 
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slope of the straight-line portion of a stress-strain curve. With respect to 
tensile testing, it may be referred to as tensile modulus. This method of 
testing is used to determine a sample's behavior under an axial 
stretching load.  Common tensile test results include elastic limit, tensile 
strength, yield point, yield strength, elongation, and Young's modulus. 
Young's Modulus is reported commonly as N/mm2 (lbs/in2), MPa (psi). 
 
Therefore, Young’s modulus can be determined from the slope of a 
stress/strain curve that was created from a tensile strength test of a 
piece of material (Figure 2.4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.7 Diagrammatic illustration of tensile stress (F) applied to tissue sample.   
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A) Quantities for defining Young’s Modulus (Pukacki et al., 2000). 
 
 The applied force (F) 
 The cross sectional area (A) 
 The Initial, unstressed length (L0) 
 The change in length due to stress (∆L) 
 
B) Define stress and strain 
 
Stress (S) is the force per unit area 
 
    F 
S = 
    A 
 
 
Stain (e) is the fractional change in length 
 
    ∆L 
e =  
    L0 
 
 
Young’s modulus (E) is defined as the ration of stress to strain 
 
  Stress   S   F/A 
E =   =   = 
  Strain   e   ∆L/L0 
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Figure 2.4.8 Stress-strain curve (determining Young’s Modulus) 
 
2.4.3.6 Differential Scanning Calorimetry (DSC) 
 
Differential scanning calorimetry (DSC) is a technique which is part of a 
group of techniques called Thermal Analysis (TA) (Ma and Harwalkar, 
1991).  TA is based upon the detection of changes in the heat content 
(enthalpy) or the specific heat of a sample with temperature.  As 
thermal energy is supplied to the sample, its enthalpy increases and its 
temperature rises by an amount determined for a given energy input 
by the specific heat of the sample.  The specific heat of a material 
changes slowly with temperature in a particular physical state, but 
alters discontinuously at a change of state. 
 
As well as increasing the sample temperature, the supply of thermal 
energy may induce physical or chemical processes in the sample, e.g. 
melting or decomposition, accompanied by a change in enthalpy, the 
latent heat of fusion and the heat of the reaction.  Such enthalpy 
changes may be detected by thermal analysis and related to the 
processes occurring in the sample. 
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In DCS, the measuring principle is to compare the rate of heat flow to 
the sample and to an inert material which is heated or cooled at the 
same rate.  Changes in the sample that is associated with absorption or 
evolution of heat cause a change in the differential heat flow which is 
then recorded as a peak.  The area below the peak is directly 
proportional to the enthalpy change and its direction indicates 
whether the thermal event is endothermic or exothermic.  For proteins, 
the thermally induced process detectable by DSC is the structural 
melting or unfolding of the molecule.  The transition of protein from a 
native to a denatured conformation is accompanied by the rupture of 
inter- and intra-molecular bonds, and the process has to occur in a 
cooperative manner to be discerned by DSC (Ma and Harwalkar, 
1991).  Analysis of a DSC thermogram enables the determination of two 
important parameters:  transition temperature peak (Tp) or maximum 
(Tmax) or denaturation (Td) temperature, and enthalpy of denaturation 
(∆H).  The denaturation temperatures are measures of the thermal 
stability of proteins, although they are influenced by the heating rate 
(Ruegg, Moor and Blanc, 1977) and protein concentration (Wright, 
1984). 
 
2.5 APPLICATIONS OF HOMOGRAFTS 
 
Despite the technical problems with valve availability, sterility, and preservation, 
homograft assessment continued through the 1960s.  This was because of the 
difficulties encountered with alternative artificial valves which include 
thromboembolism, hemorrhage, infection, hemolysis, mechanical failure, and 
impaired hemodynamic function (Stelzer and Elkins, 1989).  The homograft valve 
had an excellent beginning in the aortic position, but its use in the mitral position 
was delayed.  The particular challenges of the mitral valve led to the 
development of various support structures upon which homograft valves could 
be mounted for use in either the semilunar or the atrioventricular position. In 1967 
Angell and associates at Stanford demonstrated the use of homografts for 
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double valve replacement (Angell et al., 1968). The first patient in their series 
underwent aortic valve replacement with an unstented, fresh homograft valve 
and mitral valve replacement with a stented fresh aortic homograft.  Shortly 
thereafter, in July 1967, they performed their first triple valve replacement with 
aortic homografts, commenting that the heart sounds were indistinguishable 
from those of a normal heart.  In 1968 Ionescu reported in 63 patients the use of 
these mounted valves which had been sterilized and preserved with a 4% 
buffered formaldehyde solution (Ionescu, Wooler, Whitaker, Smith, Taylor and 
Hargreaves, 1968). 
 
The fresh aortic homograft became the preferred replacement in either isolated 
or combined valve disease (Stinson, Angell and Shumway, 1968).  During a 
period of 14 months, the Stanford group implanted homograft valves in a series 
of 93 patients including 6 multiple valve replacements.  The early results were 
encouraging and led to the bold conclusion that if valve supply is adequate, 
sterility is guaranteed, and proper cusp orientation and support are assured, the 
ideal valve replacement is available in the fresh aortic homograft (Angell et al., 
1968). 
 
Because of their superior hemodynamics and excellent durability, especially in 
younger patients, the homograft valve has been established as an excellent 
aortic valve replacement prosthesis.  With the use of homograft valves there is no 
need for the patient to commit to lifelong anticoagulation treatment (Ross, 
1962). 
 
2.5.1 Indications 
 
 Females of reproductive age 
 Any patient with bacterial endocarditis affecting the aortic valve 
 Younger patients with a small aortic root 
 Patients with a bleeding diathesis 
 Patients in whom anticoagulation is contra-indicated 
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 Homograft valves are less expensive (Langley, Livesey, Tsang, Barron, 
Lamb, Ross and Monro, 1996). 
 
2.5.2 Contra-Indications 
 
 Patients with moderate to severe hypertension 
 Patients with dilated or distorted aortic root 
 Patients with associated coronary disease 
 Patients with poor left ventricular function (Langley et al., 1996). 
 
2.5.3 Clinical Applications 
 
2.5.3.1 Adult Cardiac Surgery 
 
•  Aortic valve replacement with homograft valves  
•  Pulmonary autograft aortic valve replacement 
•  Homograft replacement of atrioventricular valves 
•  Aortic root replacement using homograft conduit (Fontan, Choussat, 
Deville, Doutremepuich, Coupilaud and Vosa, 1984). 
 
 
 
 
 
 
 
 
 
 
   Figure 2.5.1 Surgical repair using various components of the aortic homograft (A) 
Mitral valve repair, (B) Aortic root replacement (C) Mycotic aneurysm 
(adapted from Frank, Mavroudis, Backer and Rocchini, 1998). 
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2.5.3.2 Pediatric Cardiac Surgery (Congenital Defects) 
 
- Right ventricular outflow tract reconstruction 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.2 Ross-Konno procedure in neonates (The left ventricular outflow tract 
obstruction is reconstructed using the infundibular free wall of the aorta 
autograft to directly close the ventriclular septal defect.  The neo-aortic 
annulus was not reinforced, so do not limit growth.  The right ventricular 
outflow tract was reconstructed with a right ventricle pulmonary artery 
valve conduit (adapted from Lacour-Gayet, Sauer,  Ntalakoura, Müller, 
Razek, Weil and Haun, 2004). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.3 A)  Truncus Arteriosus defect B)  Surgical repair of a Truncus Arteriosus 
defect using the Rastelli procedure (adapted from Wallace, Rastelli, 
Ongley, Titus and McGoon, 1969) 
A B 
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- Pulmonary valve replacement 
- Truncus Arteriosus 
- Rastelli Procedure 
- Hypoplastic left heart 
- Fontan procedure (Fontan et al., 1984). 
 
2.5.4 Surgical Complications associated with Homograft Implantation 
 
Two of the major modes of homograft failure in aorta implants have 
been aortic regurgitation (AR) and valve calcification. 
 
The AR is associated with technical factors, such as incorrect homograft 
sizing or valve distortion due to the scalloped technique.  Late AR is most 
commonly linked to commissural misalignment, cusp distortion and 
subsequent cusp prolapse because of root enlargement.  The cusp 
deterioration is less common and occurs later, with leaflet thickening 
and occasional cusp calcification (Angell et al., 1989). 
 
Although homograft wall calcification is common severe aortic valvular 
stenosis is uncommon.  In a study conducted by Kirklin and associates 
(1993), 112 patients with available data, 77% had a mean greater than 
10mm Hg, and 94% had a mean gradient of less than 20 mm Hg (Kirklin, 
Blacstone, Maehara, Pacifico, Kirklin, Pollock and Stewart, 1987).  Leaflet 
failure causing severe stenosis is relatively unusual but may occur with 
extensive leaflet calcification. 
 
Some other causes of outflow obstruction can be linked to subvalvular 
obstruction unrelated to the homograft or, rarely, partial dehiscence of 
the valve (Kirklin et al., 1993). 
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2.5.5 Advantages and Disadvantages 
 
To date, no valve is perfect; each type has specific advantages and 
disadvantages.  Therefore, the choice of valve must be individualized to 
the patient and the disease process. 
 
2.5.5.1 Advantages 
 
•  No need for anticoagulation (absence of 
thromboembolic events) 
•  Absence of haemolysis 
•  Lack of ring/cuff of graft support (minimizing transvalvular 
gradient compared to the stented prosthetic valves 
•  Very good haemodynamic performances 
•  Higher resistance to endocarditis 
•  Attractive in children because of growth of the valve 
with somatic growth (Anastasiadis et al., 2004). 
 
 2.5.5.2 Disadvantages 
•  Ethical considerations (consent) 
•  More demanding implantation techniques 
•  Difficult to access from a “Homograft Bank” (availability) 
•  Processing techniques results in acellular grafts, which in 
time degenerates and calcifies (5-15 years) 
•  Cost implications (1400 US dollars a piece for ad hoc 
preparation with an open market value that averages 
5000 US dollars each). 
 
In general the logical use of homografts in adult cardiac surgery when 
indicated with proper surgical technique revealed very good post-
operative results and an excellent quality of life for the patient. 
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2.6 THE ANIMAL MODEL FOR HOMOGRAFT RESEARCH 
 
Pulse duplicator studies of new prostheses and subcutaneous implantation of 
new materials in small animals are commonly used methods in cardiac research.  
Although these methods have become more sophisticated, the ultimate test 
remains the successful valve implantation in a medium-sized animal. High cost of 
animal experimentation necessitates the careful selection of the most applicable 
animal model and application of the most appropriate surgical techniques 
during this kind of research.  The dog has been the traditional model for this type 
of research, but because of the strong opposition of the antivivisectionist lobby, 
other medium-sized animals have been used. 
 
Sheep were selected as the animal of choice because they have similar valve 
anatomy to humans, are readily available, and their care is simple, ensuring low 
cost and ease of handling.  They are also available in a wide selection of body 
weights and sizes (Ali, Kumar, Bjornstad and Duran, 1996). 
 
On the other hand a study performed on rat models indicated that the 
endothelium was viable for at least 40 hours postmortem (Yankah and Hertzer, 
1987). 
 
2.7 RELEVANCE OF THE STUDY 
 
Homograft valves are susceptible to calcification and structural degeneration in 
the long term.  The pathophysiological mechanism is not fully understood.  
Immunologic phenomena may contribute to the degeneration process 
(Mitchell, Jonas and Schoen, 1995).  It has been suggested that the presence of 
some viable endothelial cells at the implantation time may have a delaying 
effect in the calcification process and also might be a factor in the long term 
survival of cryopreserved homograft valves. 
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There has been extensive evaluation on the viability effects of storage of porcine 
heart valves in nutrient rich media at 4° C or in liquid nitrogen at different 
temperatures.  There is a great deal of variability in the World regarding time 
dependent damage of valvular endothelial cells after periods of warm 
ischaemia (Pompilio, Polvani, Rossoni, Porqueddu, Berti, Barajon, Petruccoili, 
Guarino, Aguggini, Biglioli and Sala, 1997). 
 
Worldwide there is great diversity regarding the optimum harvesting time of 
homograft valves.  Most heart valve banks require that donor tissue be harvested 
up to 24 hrs after death, and a few will extend the harvesting time to an absolute 
maximum of 30 - 36 hours.  Protocols worldwide also prefer the harvesting of 
homografts from a brain-dead beating heart donor within a theatre.  This limits 
the donor pool to valves explanted from transplant recipients or valves from 
hearts not suited for transplant surgery.  
 
Cadaver donor pools form the backbone of the present supply to homograft 
banks in South Africa. These donors are also quite often identified at the state 
mortuary. The average time from death to harvesting in the University of the Free 
State homograft program is 33 hours because of restrictions imposed by medico-
legal autopsies therefore exceeding the suggested 24 hour limit.  Strict 
adherence to this time limit impact negatively on our homograft processing 
ability. 
 
Despite the suggested harvest time of less than 24 hours, all programs extend 
ischaemic time due to the incubation, sterilization and processing before 
cryopreservation, which normally takes place up to 4 days for viable valves. Fresh 
albumin stored non viable homografts also have shown acceptable longterm 
results (Goffin et al., 1997). 
 
The effect of ischaemic time in the  intact cadaver donor before harvesting and 
its impact on the outcomes of homograft quality and function therefore needs to 
be clearly defined. 
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This study attempted to produce relevant scientific data to develop objective 
criteria for accepting homografts for processing and cryopreservation. This might 
lead to the safe extension of harvesting times and an increase in the homograft 
donor pool. 
 
2.7.1 Aim 
 
To determine whether the current contraints regarding cadaver 
homograft harvest time can be extended. 
 
2.7.2 Objectives 
 
•  To determine the degree of autolysis by histological evaluation of 
the pulmonary and aortic valve leaflets and arterial walls (H&E 
and SEM). 
 
•  To investigate whether a constant relationship in tensile strength 
and thermal denaturation temperature (Td) exists between the 
aorta, pulmonary and mitral valves as well as aortic and 
pulmonary arterial walls and whether mitral valve or pulmonary or 
aortic wall samples can have reliable predictive outcomes value 
in harvested valves. 
 
•  To establish the relationship between ischaemic time, tensile 
strength and thermal denaturation temperature (Td) values after 
cryopreservation. 
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4.1 INTRODUCTION 
 
All numerical results are presented in table format.  Histology (H&E and Scanning 
Electron Microscopy), thermal denaturation temperature (Td), tensile strength and 
Young’s modulus are demonstrated by representative images and graphs. 
 
Results are categorised according to the ischaemic times and temperatures.  Group A 
(control group – < 6 h Ischaemic Time at 4ºC), Group B (Cold Ischaemic Time – 24 h, 48 
h, 72 h at 4ºC), and Group C (Warm Ischaemic Time – 24 h, 48 h, 72 h at room 
temperature (23ºC) for 6 h then transported to fridge at 4ºC for 18 h, 42 h and 66 h).  
The samples were assessed in the following sequence: a) the influence of ischaemic 
time on valvular strength and morphology assessed by thermal denaturation 
temperature (Td), Tensile Strength (TS), Scanning Electron Microscopy (SEM) and light 
microscopy (H&E). 
 
Statistical data analyses include Fisher’s Exact Test (electron microscopy and histology), 
T-test (thermal denaturation temperature (Td) and tensile strength) and the Mann 
Whitney test (Young’s modulus). 
 
4.2 THE INFLUENCE OF ISCHAEMIC TIME ON HARVESTED VALVULAR HOMOGRAFTS 
 
 4.2.1 Temperature 
 
Figure 4.2.1 indicates the mean temperature decline of warm and cold ischaemic 
groups from death till homograft procurement.  After euthanasia, the carcasses 
CHAPTER 4 
RESULTS 
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(Group B) were placed in a temperature controlled cold room at 4ºC.  A 
temperature probe was placed inside the thoracic cavity next to the heart to 
continuously measure cooling of l the carcasses to 4ºC.  Group C was exposed to 
room temperature (23ºC) for six hours before the carcasses were transported to 
the cold room and monitored until it reached 4˚C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.1 Mean temperature decline of sheep carcasses after euthanasia (Group B (blue) (STD 
0.65˚C) and Group C (red) (STD 0.43 ˚C). 
 
4.2.2 Thermal Denaturation Temperature (Td) 
 
The DSC technique allows for the derivation of the heat capacity of proteins as a 
function of temperature [thermal denaturation temperature (Td) measured in 
degrees of Celsius (ºC)].  Figure 4.2.2 demonstrates the peak temperature at which 
the triple helix protein molecules unfold during DSC of the pulmonary leaflets in 
Group A, B, and C. 
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Figure 4.2.2 Example of thermal denaturation temperature (Td), graphs for pulmonary leaflets 
 
Table 4.2.2 represents the thermal denaturation temperature (Td) results for Group A (< 6 
h Ischaemic Time), Group B (24 h, 48 h, 72 h Cold Ischaemic Time) and Group C (24 h, 
48 h, 72 h Warm Ischaemic Time).  Statistical significant differences of group and inter-
group comparisons in relation to varying harvesting times are discussed under 4.2.7. 
 
 
 
 
 
 
 
 
66.68 
0.5 
°C 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90
 
W/g 
LAB: METTLER                                                                                                                                              STAR* SW 9.00 
 
[ IT = Ischaemic Time; CIT = Cold Ischaemic Time; WIT = Warm Ischaemic Time] 
Group A (< 6 h IT) 
PULMONARY LEAFLETS (Group A, B and C) 
Group B (72 h CIT) 
Group B (48 h CIT) 
Group C (24 h WIT) 
Group B (24 h CIT) 
Group C (48 h WIT) 
Group C (72 h WIT) 
70.20 
71.04 
70.98 
69.83 
69.66 
69.62 
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Table 4.2.2 Thermal denaturation temperature (Td) for Group A, B and C 
 
 
        
 GROUP A GROUP B GROUP C 
n 5 5 5 5 5 5 5 
TIME < 6 h 24 h 48 h 72 h 24 h 48 h 72 h 
AORTIC LEAFLET 
MEAN 66.95 70.16 69.83 70.61 70.70 69.22 69.58 
STD 0.42 0.83 0.47 0.85 1.31 0.88 1.12 
MINIMUM 66.46 69.2 69.39 69.85 69.55 67.98 68.67 
MAXIMUM 67.38 71.47 70.62 71.73 72.94 70.12 71.5 
MEDIAN 66.95 70.04 69.7 70.14 70.33 69.67 69.17 
PULMONARY LEAFLET 
MEAN 67.16 70.25 71.25 71.01 70.74 69.60 69.63 
STD 1.31 0.76 1.17 0.36 0.80 0.76 0.40 
MINIMUM 66.1 69.24 69.65 70.53 69.95 68.28 69.28 
MAXIMUM 69.35 71.38 72.7 71.41 71.61 70.15 70.32 
MEDIAN 66.68 70.2 71.04 70.98 70.48 69.91 69.49 
MITRAL LEAFLET 
MEAN 68.32 71.19 69.99 71.28 71.76 70.35 69.08 
STD 0.92 1.02 0.63 0.65 3.27 1.46 0.71 
MINIMUM 67.46 69.62 69.41 70.68 69.47 68.55 68.48 
MAXIMUM 69.74 72.31 70.71 72 77.39 72.59 70.3 
MEDIAN 68.33 71.21 69.68 70.93 70.55 70.03 68.93 
AORTIC WALL 
MEAN 69.68 70.40 69.96 70.81 70.93 70.36 69.95 
STD 0.49 0.29 0.55 0.94 0.87 0.46 0.75 
MINIMUM 69.15 70.07 69.16 69.38 69.83 69.69 69.21 
MAXIMUM 70.39 70.79 70.71 71.63 72.21 70.83 71.05 
MEDIAN 69.47 70.45 69.94 70.96 70.85 70.31 69.65 
PULMONARY WALL 
MEAN 70.57 70.57 71.19 72.44 71.12 71.36 70.02 
STD 1.03 1.12 1.13 2.85 1.15 1.01 0.59 
MINIMUM 69.43 68.8 69.75 70.78 69.53 70.81 69.47 
MAXIMUM 71.95 71.49 72.75 77.5 72.58 73.15 70.94 
MEDIAN 70.3 71.15 70.9 71.16 71.21 70.91 70.03 
        
 
 
[GROUP A = Control Group (< 6 h Ischaemic Time); GROUP B = Cold Ischaemic Time (24 h, 48 h, 72 h); GROUP C = Warm 
Ischaemic Time (24 h, 48 h, 72 h); Td = Thermal Denaturation Temperature (ºC)] 
 
4.2.3 Tensile Strength 
 
Tensile strength testing was performed to determine the breakage point measured in 
MPa of the valve leaflets and the arterial wall tissue (Figure 4.2.3a).  Tensile strength 
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testing lends itself to greater variance due to operational difficulties (small sample size 
and slippage of valve leaflets (Figure 4.2.3b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.3(a) Example of Tensile Strength testing performed on a mitral valve leaflet (CIT = Cold 
Ischaemic Time; MPa = Mega Pascal; N = Newton; h = hour). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2.3 provides a statistical summary of the tensile strength test performed on 
Group A, B and C.  In Group A twenty samples were analysed to minimise the degree 
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TENSILE STRENGTH MITRAL LEAFLET – 48 h CIT 
Figure 4.2.3(b)  Example of operational difficulty (slippage of leaflet in mechanical grip  
 during testing) 
 
TENSILE STRENGTH PULMONARY LEAFLET -24 h CIT 
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of statistical variance.  Statistical significant differences of group and inter-group 
comparisons in relation to varying harvesting times are discussed under 4.2.7. 
 
Table 4.2.3 Tensile Strength (MPa) for Group’s A, B and C 
 
    
  
GROUP 
A 
 
 
GROUP B 
 
 
GROUP C 
 
n 20 5 5 5 5 5 5 
TIME < 6 h 24 h 48 h 72 h 24 h 48 h 72 h 
AORTIC LEAFLET 
      
 
MEAN 1.45 2.66 4.56 3.82 3.72 5.51 4.45 
STD 0.75 0.72 0.63 2.03 1.06 1.14 1.82 
MINIMUM 0.19 1.74 4.05 1.14 2.05 3.89 1.85 
MAXIMUM 2.67 3.54 5.59 6.78 4.72 6.55 6.43 
MEDIAN 1.35 2.45 4.50 3.67 4.02 5.82 4.40 
PULMONARY LEAFLET 
MEAN 1.24 2.57 2.93 3.03 4.10 4.52 3.17 
STD 0.79 1.07 0.50 1.02 0.86 0.84 1.73 
MINIMUM 0.25 1.54 2.45 1.44 2.94 3.28 0.55 
MAXIMUM 3.73 4.11 3.65 4.09 4.80 5.28 4.97 
MEDIAN 1.01 2.22 2.93 3.04 4.65 5.00 3.29 
MITRAL LEAFLET 
MEAN 2.27 4.94 5.84 4.94 11.80 7.11 8.79 
STD 1.54 4.40 3.58 4.40 1.64 3.70 2.39 
MINIMUM 0.29 1.13 1.18 1.13 9.99 3.09 7.12 
MAXIMUM 6.13 12.44 9.36 12.44 13.98 12.05 12.77 
MEDIAN 2.25 3.82 7.87 3.82 12.13 7.29 7.69 
AORTIC WALL 
      
 
MEAN 1.34 1.09 1.36 1.33 1.28 1.49 1.22 
STD 0.29 0.24 0.39 0.47 0.34 0.30 0.14 
MINIMUM 0.80 0.69 0.82 0.74 0.98 1.26 1.06 
MAXIMUM 1.87 1.29 1.75 1.94 1.85 2.03 1.45 
MEDIAN 1.30 1.13 1.31 1.33 1.18 1.40 1.21 
PULMONARY WALL       
MEAN 1.04 1.03 0.95 1.16 1.18 1.41 0.87 
STD 0.36 0.27 0.22 0.34 0.41 0.32 0.22 
MINIMUM 0.55 0.78 0.64 0.78 0.59 1.07 0.65 
MAXIMUM 2.26 1.46 1.15 1.68 1.68 1.80 1.11 
MEDIAN 1.00 0.96 1.01 1.18 1.19 1.35 0.82 
        
 
[GROUP A = Control Group (< 6 h Ischaemic Time); GROUP B = Cold Ischaemic Time (24 h, 48 h, 72 h); GROUP C = Warm 
Ischaemic Time (24 h, 48 h, 72 h); MPa=Mega Pascal] 
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4.2.4 Young’s Modulus 
 
The stiffness of a material represents the ability of materials to resist deformation.  
Stiffness is commonly characterized by the slope of the linear region of a stress-strain 
curve, also referred to as Young’s Modulus (Julien et al., 1997). 
 
Figure 4.2.4 indicates a stress-strain curve of a mitral valve leaflet (48 h cold ischaemic 
times) from which the Young’s modulus was calculated.  The results of the calculated 
Young’s modulus are displayed in terms of the mean, standard deviation, median, 
maximum and minimum in Table 4.2.4 for Group A, B and C.  Statistical significant 
differences of group and inter-group comparisons in relation to varying harvesting times 
are discussed under 4.2.7. 
 
 
 
Figure 4.2.4 Young’s Modulus calculated from the slope of the linear region of the Stress Stain curve for a 
mitral valvular leaflet after 48 h CIT (CIT=Cold Ischaemic Time; MPa=Mega Pascal; h = hour). 
 
 
 
 
 
 
 
 
 
 
S
tr
e
ss
 (
M
P
a
) 
Strain 
Greatest Slope Point #2 
Greatest Slope Point #1 
YOUNG’S MODULUS MITRAL LEAFLET – 48 h CIT 
0.0 1.0 2.0 3.0 4.0 5.0 
0.0 
1.0 
2.0 
3.0 
4.0 
5.0 
6.0 
7.0 
8.0 
 #2 Stress - #1 Stress 
YM =   
 #2 Strain - #1 Strain 
 
      = 4.217949 – 2.649055 
  
 0.345027 – 0.301728 
 
 1.568894 
      =  
 0.043298 
 
      = 36.23457 (MPa) 
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Table 4.2.4 Young’s Modulus (MPa) calculated for Group A, B and C 
 
    
  
GROUP A 
 
 
GROUP B 
 
 
GROUP C 
 
n 20 5 5 5 5 5 5 
TIME < 6 h 24 h 48 h 72 h 24 h 48 h 72 h 
AORTIC LEAFLET 
      
 
MEAN 5.42 10.29 18.21 14.98 15.07 20.16 14.78 
STD 4.33 3.72 7.93 7.50 5.41 4.77 3.88 
MINIMUM 0.68 4.12 9.47 5.37 7.06 13.82 9.15 
MAXIMUM 13.67 13.69 27.74 26.34 20.38 26.74 18.51 
MEDIAN 3.77 10.58 19.44 14.39 17.89 20.24 14.18 
PULMONARY LEAFLET 
MEAN 5.68 9.93 9.25 10.73 14.60 11.68 10.49 
STD 4.57 2.63 5.02 4.33 3.18 3.70 5.62 
MINIMUM 0.84 7.34 2.82 4.21 9.94 7.58 1.83 
MAXIMUM 18.42 14.01 15.62 13.95 17.55 16.89 17.34 
MEDIAN 4.78 8.85 10.78 13.37 16.38 10.92 10.86 
MITRAL LEAFLET 
MEAN 7.79 19.44 24.52 33.42 47.47 25.06 30.09 
STD 7.27 15.95 21.04 14.98 2.68 10.41 4.48 
MINIMUM 0.39 3.08 1.62 15.62 43.83 15.35 25.71 
MAXIMUM 30.96 45.78 45.65 47.91 49.98 42.00 36.29 
MEDIAN 6.25 15.43 36.23 37.65 48.45 24.10 28.04 
AORTIC WALL 
       
 
MEAN 3.19 3.43 4.11 4.40 3.62 4.31 4.80 
STD 0.65 0.95 1.24 1.37 0.77 0.48 0.51 
MINIMUM 2.12 2.17 2.49 2.44 2.95 3.57 4.28 
MAXIMUM 4.11 4.45 5.41 6.04 4.80 4.85 5.53 
MEDIAN 3.38 3.23 4.54 4.84 3.38 4.31 4.76 
PULMONARY WALL       
MEAN 2.06 3.21 3.26 3.81 3.72 5.04 2.56 
STD 0.77 0.90 0.93 1.31 1.26 0.78 0.75 
MINIMUM 1.17 2.31 2.05 2.65 1.93 4.41 1.75 
MAXIMUM 4.45 4.62 4.25 5.88 5.00 6.26 3.60 
MEDIAN 2.00 2.90 3.32 3.68 3.68 4.59 2.35 
        
 
[GROUP A = Control Group (< 6 h Ischaemic Time); GROUP B = Cold Ischaemic Time (24 h, 48 h, 72 h); GROUP C = Warm 
Ischaemic Time (24 h, 48 h, 72 h); MPa=Mega Pascal] 
 
 
 
 
 
 
C h a p t e r  4  –  R e s u l t s                                             P a g e  | 63 
 
4.2.5 Scanning Electron Microscopy (SEM) 
 
Scanning electron microscopy was used to evaluate the integrity and quality of the endothelial 
surface of the valvular leaflets and arterial walls.  A special scoring system was adopted and 
modified to categorize the samples in three categories (I-III) (Table 4.2.5.1). 
 
Table 4.2.5.1 Summary of SEM scoring system – Category I, II, and III 
 
 
CATEGORY I 
 
CATEGORY II 
 
CATEGORY III 
 
The basal membrane and 
endothelial cells are completely 
absent 
 
Scattered endothelial cells with 
the basal membrane intact. 
 
Tissue surface almost completely 
or predominantly covered with 
endothelial cells. 
 
 
 
 
 
 
 
 
 
 
 
Pulmonary Leaflet – 72 h CIT 
 
 
 
 
 
 
 
 
 
 
 
 
Pulmonary Leaflet – 24 h CIT 
 
 
 
 
 
 
 
 
 
 
 
 
Pulmonary Leaflet – < 6 h IT 
 
 
 
 
 
 
 
 
 
 
 
 
Aortic Wall – 48 h WIT 
 
 
 
 
 
 
 
 
 
 
 
 
Pulmonary Wall – < 6 h IT 
 
 
 
 
 
 
 
 
 
 
 
 
Aortic Leaflet – < 6 h IT 
 
 
 
 
 
 
 
 
 
 
 
 
Aortic Leaflet – 48 h WIT 
 
 
 
 
 
 
 
 
 
 
 
 
Aortic Leaflet – 24 h WIT 
 
 
 
 
 
 
 
 
 
 
 
 
Mitral Leaflet – < 6 h IT 
 
 
[CIT = Cold Ischaemic Time; WIT = Warm Ischaemic Time; IT = Ischaemic Time; h = hour] 
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The SEM results are displayed in a frequency table (Table 4.2.5.2).  Each sample was 
represented by 4-5 images taken at different sites to provide an overall perspective on 
the quality of the surface area in each sample.  Statistically significant differences of 
group and inter-group comparisons in relation to varying harvesting times are discussed 
under 4.2.7. 
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4.2.6 Haematoxylin and Eosin stain (H&E) 
 
The H&E histological stain was used to evaluate changes in the cellular composition 
and tissue architecture.  The samples were graded as either being normal (Figure 
4.2.6a) or demonstrating the presence of autolysis (Figure 4.2.6b). 
 
Autolysis were defined as necrotic cells that showed increased eosinophilia 
attributed in part to loss of the normal basophilia imparted by the RNA in the 
cytoplasm and in part to the increased binding of eosin to denatured 
intracytoplasmic proteins.  The cells may have a more glassy homogeneous 
appearance than that of normal cells, mainly as a result of the loss of glycogen 
particles.  When enzymes have digested the cytoplasmic organelles, the cytoplasm 
becomes vacuolated and appears moth-eaten.  Finally, calcification of the dead 
cells may occur (Kumar, Abbas, Fausto, Robbins and Cotran, 2005.) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.6 Haematoxylin and Eosin stain performed on (a) normal valve leaflets and (b) autolytic 
valve leaflets 
 
 
The H&E results are displayed in a frequency table (Table 4.2.6) for Group’s A, B and 
C.  Statistical significant differences of group and inter-group comparisons in relation 
to varying harvesting times are discussed under 4.2.7. 
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4.2.7 Inter-group and group comparisons in relation to varying harvested 
ischaemic times 
 
4.2.7.1 Group B (24 h vs. 48 h vs. 72 h Cold Ischaemic Time) 
 
The only statistically significant difference (p < 0.05) was found between the thermal 
denaturation temperature of mitral valve leaflet at 48 h and 72 h (Table 4.2.7.1).  
Tensile strength, Young’s Modulus, SEM and H&E did not reveal any statistically 
significant differences (p > 0.05) at 24 h, 48 h and 72 h. 
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Table 4.2.7.1 Group B (24 h vs. 48 h vs. 72 h Cold Ischaemic Time) 
 
      
A
O
R
TI
C
 L
E
A
FL
E
T 
Td 
            TENSILE  
          STRENGTH 
         YOUNG’S  
         MODULUS 
             SEM II               H & E 
IT      p-value IT p-value IT    p-value   IT      p-value        IT    p-value 
24 vs. 48 vs. 
72 h 
0.282 
24 vs. 48 vs. 
72 h 
0.105 
24 vs. 48 vs. 
72 h 
0.209 
24 vs. 48 vs. 
72 h 
0.106 
24 vs. 48 vs. 
72 h 
EM 
24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 
24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 
48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 
P
U
LM
O
N
A
R
Y
 
LE
A
FL
E
T 
24 vs. 48 vs. 
72 h 
0.184 
24 vs. 48 vs. 
72 h 
0.702 
24 vs. 48 vs. 
72 h 
0.853 
24 vs. 48 vs. 
72 h 
0.198 
24 vs. 48 vs. 
72 h 
EM 
24 vs. 48 - 24 vs. 48 - 24 vs. 48 - 24 vs. 48 - 24 vs. 48 - 
24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 
48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 
M
IT
R
A
L 
LA
E
FL
E
T 
24 vs. 48  
vs. 72 h 
0.045 
24 vs. 48  
vs. 72 h 
0.351 
24 vs. 48  
vs. 72 h 
0.466 
24 vs. 48  
vs. 72 h 
0.754 
24 vs. 48  
vs. 72 h 
EM 
24 vs. 48 h 0.055 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 
24 vs. 72 h 0.872 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 
48 vs. 72 h 0.013 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 
A
O
R
TI
C
 W
A
LL
 
24 vs. 48 vs. 
72 h 
0.158 
24 vs. 48 vs. 
72 h 
0.487 
24 vs. 48 vs. 
72 h 
0.447 
24 vs. 48 vs. 
72 h 
1.000 
24 vs. 48 vs. 
72 h 
EM 
24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 
24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 
48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 
P
U
LM
O
N
A
R
Y
 
W
A
LL
 
24 vs. 48 vs. 
72 h 
0.314 
24 vs. 48 vs. 
72 h 
0.516 
24 vs. 48 vs. 
72 h 
0.625 
24 vs. 48 vs. 
72 h 
1.000 
24 vs. 48 vs. 
72 h 
EM 
24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 
24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 
48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 
 
 
p<0.05 = statistically significant; p>0.05 = not statistically significant 
(Td = Thermal Denaturation Temperature (ºC); IT = Ischaemic Time (h); SEM = Scanning Electron Microscopy; H&E = 
Haematoxylin and Eosin; h =hours; EM = Equal Mean; - No Values) 
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4.2.7.2 Group C (24 h vs. 48 h vs. 72 h Warm Ischaemic Time) 
 
Table 4.2.7.2 represents a summary of the inter-group relationship between 24 
h, 48 h and 72 h.  The thermal denaturation temperature showed a 
statistically significant difference (p < 0.05) between pulmonary valve leaflets 
at 24 h and 72 h. 
 
The Young’s Modulus calculated from the stress-stain curve for mitral valve 
leaflets indicated a statistically significant difference (p < 0.05) between 24 h 
and 48 h, as well as between 24 h and 72 h.  The aortic wall showed a 
significant difference (p < 0.05) between tissue at 24 h and 72 h.  Pulmonary 
wall tissue showed a significant difference (p < 0.05) between tissues at 48 h 
and 72 h. 
 
H&E results showed a statistically significant difference (p < 0.05) between all 
sample tested (mitral, aortic and pulmonary valve leaflets between 24 h and 
48 h, 24 h and 72 h, 48 h and 72 h; pulmonary and aortic wall between 24 h 
and 48 h, 24 h and 72 h, 48 h and 72 h. 
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Table 4.2.7.2 Group C (24 h vs. 48 h vs. 72 h Warm Ischaemic Time) 
 
p < 0.05 = statistically significant; p > 0.05 = not statistically significant 
(Td = Thermal Denaturation Temperature (ºC); IT = Ischaemic Time (h); SEM = Scanning Electron Microscopy; H&E = 
Haematoxylin and Eosin; h =hours; – = No Values; EM = Equal Mean) 
 
      
 A
O
R
TI
C
 L
E
A
FL
E
T 
Td 
TENSILE 
STRENGTH 
YOUNG’S 
MODULUS 
SEM  H & E 
        IT p-value     IT   p-value       IT p-value IT     p-value         IT p-value 
24 vs. 48 vs. 
72 h 
0.137 
24 vs. 48 vs. 
72 h 
0.162 
24 vs. 48 vs. 
72 h 
0.172 
24 vs. 48 vs. 
72 h 
p<0.001 
24 vs. 48 vs. 
72 h 
0.006 
24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h 1.000 
24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h 0.008 
48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h 0.048 
  
  
  
 P
U
LM
O
N
A
R
Y
 
LE
A
F
LE
T 
24 vs. 48 vs. 
72 h 
0.034 
24 vs. 48 vs. 
72 h 
0.238 
24 vs. 48 vs. 
72 h 
0.333 
24 vs. 48 vs. 
72 h 
0.222 
24 vs. 48 vs. 
72 h 
0.009 
24 vs. 48 h 0.051 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h 0.167 
24 vs. 72 h 0.025 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h 0.008 
48 vs. 72 h 0.944 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h 0.444 
M
IT
R
A
L 
LA
E
FL
E
T 
24 vs. 48 vs. 
72 h 
0.175 
24 vs. 48 vs. 
72 h 
0.052 
24 vs. 48 vs. 
72 h 
0.001 
24 vs. 48 vs. 
72 h 
0.320 
24 vs. 48 vs. 
72 h 
0.009 
24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h 0.009 24 vs. 48 h - 24 vs. 48 h 0.444 
24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h 0.009 24 vs. 72 h - 24 vs. 72 h 0.008 
48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h 0.175 48 vs. 72 h - 48 vs. 72 h 0.167 
A
O
R
TI
C
 W
A
LL
 
24 vs. 48 vs. 
72 h 
0.134 
24 vs. 48 vs. 
72 h 
0.294 
24 vs. 48 vs. 
72 h 
0.028 
24 vs. 48 vs. 
72 h 
EM 
24 vs. 48 vs. 
72 h 
0.001 
24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h 0.117 24 vs. 48 h - 24 vs. 48 h - 
24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h 0.047 24 vs. 72 h - 24 vs. 72 h 0.008 
48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h 0.175 48 vs. 72 h - 48 vs. 72 h 0.008 
P
U
LM
O
N
A
R
Y
 
W
A
LL
 
24 vs. 48 vs. 
72 h 
0.098 
24 vs. 48 vs. 
72 h 
0.063 
24 vs. 48 vs. 
72 h 
0.005 
24 vs. 48 vs. 
72 h 
EM 
24 vs. 48 vs. 
72 h 
0.006 
24 vs. 48 h - 24 vs. 48 h - 24 vs. 48 h 0.175 24 vs. 48 h - 24 vs. 48 h 0.048 
24 vs. 72 h - 24 vs. 72 h - 24 vs. 72 h 0.117 24 vs. 72 h - 24 vs. 72 h 0.008 
48 vs. 72 h - 48 vs. 72 h - 48 vs. 72 h 0.009 48 vs. 72 h - 48 vs. 72 h 1.000 
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4.2.7.3 Group A (< 6 h Ischaemic Time) vs. Group B (24 h vs. 48 h vs. 72 h Cold 
Ischaemic Time) 
 
The general impression of Table 4.2.7.3 is that a statistically significant 
difference exists in the majority of the tests performed with the exception of 
H& E (none of the samples showed autolysis).  
 
Table 4.2.7.3 Group A (< 6 h Ischaemic Time) vs. Group B (24 h vs. 48 h vs. 72 h Cold 
Ischaemic Time) 
      
A
O
R
TI
C
 L
E
A
F
LE
T 
Td 
TENSILE  
STRENGTH 
YOUNG’S  
MODULUS 
SEM  H&E 
IT p-value  IT p-value        IT p-value        IT p-value       IT       p-value 
24 h p<0.001 24 h 0.004 24 h 0.035 24 h p<0.001 24 h EM 
48 h p<0.001 48 h p<0.001 48 h 0.004 48 h p<0.001 48 h EM 
72 h p<0.001 72 h 0.058 72 h 0.005 72 h 0.006 72 h EM 
  
  
P
U
LM
O
N
A
R
Y
 
  
  
  
  
LE
A
FL
E
T 
24 h 0.002 24 h 0.005 24 h 0.025 24 h 0.179 24 h EM 
48 h 0.001 48 h p<0.001 48 h 0.103 48 h 0.003 48 h EM 
72 h 0.002 72 h 0.014 72 h 0.036 72 h 0.074 72 h EM 
M
IT
R
A
L 
LA
E
F
LE
T 
24 h 0.002 24 h 0.250 24 h 0.035 24 h 0.007 24 h EM 
48 h 0.010 48 h 0.089 48 h 0.277 48 h 0.007 48 h EM 
72 h p<0.001 72 h 0.053 72 h 0.001 72 h 0.003 72 h EM 
A
O
R
TI
C
 W
A
LL
 24 h 
0.022 24 h 0.081 24 h 0.054 24 h p<0.001 24 h EM 
48 h 0.425 48 h 0.913 48 h 0.118 48 h p<0.001 48 h EM 
72 h 0.044 72 h 0.936 72 h 0.067 72 h p<0.001 72 h EM 
  
  
 P
U
LM
O
N
A
R
Y
  
  
  
 
  
  
  
  
  
 W
A
LL
 
24 h 1.000 24 h 0.933 24 h 0.007 24 h p<0.001 24 h EM 
48 h 0.390 48 h 0.606 48 h 0.015 48 h p<0.001 48 h EM 
72 h 0.226 72 h 0.519 72 h 0.004 72 h p<0.001 72 h EM 
 
p<0.05 = statistically significant; p>0.05 = no statistically significant 
(Td = Thermal Denaturation Temperature (ºC); IT = Ischaemic Time (h); SEM = Scanning Electron Microscopy; H&E = 
Haematoxylin and Eosin; h =hours; EM = Equal Mean) 
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4.2.7.4 Group A (< 6 h Ischaemic Time) vs. Group C (24 h vs. 48 h vs. 72 h Warm 
Ischaemic Time) 
 
Table 4.2.7.4 summarizes the statistical differences (p-values) between Group 
A and C.  Major statistical differences were present between samples of 
Group A and samples of Group B. 
 
Table 4.2.7.4 Group A (< 6 h Ischaemic Time) vs. Group C (24 h vs. 48 h vs. 72 h Warm 
Ischaemic Time) 
 
p < 0.05 = statistically significant; p > 0.05 = not statistically significant (Td = Thermal Denaturation Temperature (ºC); IT = 
Ischaemic Time (h); SEM = Scanning Electron Microscopy; H&E = Hematoxylin and Eosin; h =hours; EM = Equal Mean) 
      
A
O
R
TI
C
 L
E
A
FL
E
T 
Td 
TENSILE 
STRENGTH 
YOUNG’S 
MODULUS 
SEM      H & E 
    IT p-value     IT p-value IT p-value IT         p-value       IT p-value 
24 h 0.002 24 h p<0.001 24 h 0.007 24 h 0.005 24 h EM 
48 h 0.001 48 h p<0.001 48 h 0.001 48 h p<0.001 48 h 1.000 
72 h 0.004 72 h 0.020 72 h 0.003 72 h 0.001 72 h 0.008 
P
U
LM
O
N
A
R
Y
 
LE
A
FL
E
T 
24 h 0.001 24 h p<0.001 24 h 0.004 24 h 0.001 24 h EM 
48 h 0.007 48 h p<0.001 48 h 0.015 48 h 0.001 48 h 0.167 
72 h 0.011 72 h 0.067 72 h 0.103 72 h 0.006 72 h 0.008 
M
IT
R
A
L 
LA
E
FL
E
T 
24 h 0.077 24 h p<0.001 24 h 0.001 24 h 0.002 24 h EM 
48 h 0.030 48 h 0.041 48 h 0.003 48 h p<0.001 48 h 0.444 
72 h 0.186 72 h p<0.001 72 h 0.001 72 h 0.001 72 h 0.008 
A
O
R
TI
C
 W
A
LL
 
24 h 0.023 24 h 0.689 24 h 0.308 24 h p<0.001 24 h EM 
48 h 0.054 48 h 0.300 48 h 0.004 48 h p<0.001 48 h EM 
72 h 0.516 72 h 0.382 72 h 0.001 72 h p<0.001 72 h 0.008 
P
U
LM
O
N
A
R
Y
 
W
A
LL
 
24 h 0.452 24 h 0.468 24 h 0.015 24 h p<0.001 24 h EM 
48 h 0.259 48 h 0.054 48 h 0.001 48 h p<0.001 48 h 0.048 
72 h 0.329 72 h 0.310 72 h 0.154 72 h p<0.001 72 h 0.008 
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4.2.7.5 Group B (24 h vs. 48 h vs. 72 h Cold Ischaemic Time) vs. Group C (24 h vs. 48 h 
vs. 72 h Warm Ischaemic Time) 
 
Table 4.2.7.5 represents a statistical summary between group B and Group C.  
The thermal denaturation temperature (Td) showed a statistically significant 
difference (p < 0.05) at 48 h (CIT & WIT), and 72 h (CIT & WIT) for pulmonary 
valve leaflets and 72 h (CIT & WIT) for mitral valve leaflets. 
 
For the tensile strength tests, statistically significant differences (p < 0.05) were 
evident 24 h (CIT & WIT) and 48 h (CIT & WIT) for pulmonary valve leaflets; 24 h 
(CIT & WIT) for mitral valve leaflets; 48 h (CIT & WIT) for the aortic wall and 48 h 
(CIT & WIT) for the pulmonary wall. 
 
The Young’s Modulus calculated from the stress-stain curve indicated a 
statistically significant difference (p < 0.05) at 24 h (CIT & WIT) for pulmonary 
valve leaflets; 24 h (CIT & WIT) for mitral valve leaflets and 48 h (CIT & WIT) for 
the pulmonary wall. 
 
SEM results demonstrated statistically significant differences (p < 0.05) were 
found for the SEM results at the 48 h (CIT & WIT) for aortic valve leaflets; 24 h 
(CIT & WIT) and 48 h (CIT & WIT) for pulmonary valve leaflets and 48 h (CIT & 
WIT) for mitral valve leaflets. 
 
All the samples in Group C showed the presence of autolysis after 72 h 
ischaemic time.  H&E histology results showed a statistically significant 
difference (p < 0.05) among the samples tested for the mitral, aortic and 
pulmonary valve leaflets at 72 h (CIT & WIT) as well as samples tested for 
pulmonary wall tissue at 48 h and 72 h (CIT & WIT) and aortic wall tissue at 72 h 
(CIT & WIT). 
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Table 4.2.7.5 Group B (24 h vs. 48 h vs. 72 h Cold Ischaemic Time) vs. Group C (24 h vs. 
48 h vs. 72 h Warm Ischaemic Time) 
 
      
A
O
R
TI
C
 L
E
A
FL
E
T 
Td 
TENSILE 
STRENGTH 
YOUNG’S 
MODULUS 
SEM H&E 
IT p-value IT p-value IT p-value IT p-value IT p-value 
24 h 0.462 24 h 0.101 24 h 0.143 24 h 0.509 24 h EM 
48 h 0.210 48 h 0.140 48 h 0.651 48 h 0.000 48 h 1.000 
72 h 0.141 72 h 0.623 72 h 0.959 72 h 0.260 72 h 0.008 
P
U
LM
O
N
A
R
Y
 
LE
A
FL
E
T 
24 h 0.357 24 h 0.037 24 h 0.035 24 h 0.000 24 h EM 
48 h 0.030 48 h 0.007 48 h 0.409 48 h 0.024 48 h EM 
72 h p<0.00 72 h 0.883 72 h 0.941 72 h 0.302 72 h 0.008 
M
IT
R
A
L 
LE
A
F
LE
T 
24 h 0.724 24 h 0.022 24 h 0.016 24 h 0.123 24 h EM 
48 h 0.621 48 h 0.596 48 h 0.960 48 h 0.004 48 h 0.444 
72 h 0.001 72 h 0.902 72 h 0.655 72 h 0.235 72 h 0.008 
A
O
R
TI
C
 W
A
LL
 24 h 0.251 24 h 0.506 24 h 0.746 24 h 1.000 24 h EM 
48 h 0.244 48 h 0.030 48 h 0.754 48 h 1.000 48 h 0.167 
72 h 0.147 72 h 0.141 72 h 0.569 72 h 1.000 72 h 0.008 
P
U
LM
O
N
A
R
Y
 
W
A
LL
 
24 h 0.469 24 h 0.506 24 h 0.483 24 h 1.000 24 h EM 
48 h 0.814 48 h 0.030 48 h 0.011 48 h 1.000 48 h 0.048 
72 h 0.131 72 h 0.141 72 h 0.101 72 h 1.000 72 h 0.008 
 
 
p<0.05 = statistically significant; p>0.05 = no statistically significant; p =1.00 = Equal mean 
(Td = Thermal Denaturation Temperature; IT = Ischaemic Time; SEM = Scanning Electron Microscopy; H&E = Haematoxylin 
and Eosin; h =hours; EM= Equal Mean) 
 
4.3 THE QUALITY OF TISSUE MORPHOLOGY OF HARVESTED VALVULAR HOMOGRAFTS 
 
After evaluating the influence of harvesting time all the results were re-classified 
according to their morphological quality (SEM categorization I-III).  The SEM 
categorization was summarized in Table 4.3.1. 
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Table 4.3.1 SEM categorization criteria 
 
 
Category I 
The basal membrane and 
endothelial cells are 
completely absent 
 
Category II 
Scattered endothelial cells 
and the basal membrane 
are still intact. 
 
Category III 
The tissue surface is almost 
completely endothelialyzed. 
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Table 4.3.2 represents the morphological distribution of the samples according to the 
SEM categorization I-III in a frequency table. 
 
Table 4.3.2 Morphological distribution according to SEM categorization I-III 
 
 
  
Category I Category II Category III 
 
Hour n % n % n % 
AORTIC LEAFLET 
GROUP A < 6 h 0 0.00 1 2.86 4 11.43 
GROUP B 
24 h 0 0.00 5 14.29 0 0.00 
48 h 1 2.86 4 11.43 0 0.00 
72 h 1 2.86 4 11.43 0 0.00 
GROUP C 
24 h 0 0.00 5 14.29 0 0.00 
48 h 1 2.86 4 11.43 0 0.00 
72 h 2 5.71 3 8.57 0 0.00 
TOTAL 
 
5 14.29 26 74.29 4 11.43 
PULMONARY LEAFLET 
GROUP A < 6 h 0 0.00 0 0.00 5 14.29 
GROUP B 
24 h 0 0.00 2 5.71 3 8.57 
48 h 1 2.86 3 8.57 1 2.86 
72 h 1 2.86 2 5.71 2 5.71 
GROUP C 
24 h 3 8.57 1 2.86 1 2.86 
48 h 3 8.57 1 2.86 1 2.86 
72 h 1 2.86 3 8.57 1 2.86 
TOTAL 
 
9 25.71 12 34.29 14 40.00 
MITRAL LEAFLET 
GROUP A < 6 h 0 0.00 4 11.43 1 2.86 
GROUP B 
24 h 3 8.57 2 5.71 0 0.00 
48 h 3 8.57 2 5.71 0 0.00 
72 h 4 11.43 1 2.86 0 0.00 
GROUP C 
24 h 4 11.43 1 2.86 0 0.00 
48 h 5 14.29 0 0.00 0 0.00 
72 h 5 14.29 0 0.00 0 0.00 
TOTAL 
 
24 68.57 10 28.57 1 2.86 
AORTIC WALL 
GROUP A < 6 h 0 0.00 5 14.29 0 0.00 
GROUP B 
24 h 5 14.29 0 0.00 0 0.00 
48 h 5 14.29 0 0.00 0 0.00 
72 h 5 14.29 0 0.00 0 0.00 
GROUP C 
24 h 5 14.29 0 0.00 0 0.00 
48 h 5 14.29 0 0.00 0 0.00 
72 h 5 14.29 0 0.00 0 0.00 
TOTAL 
 
30 85.71 5 14.29 0 0.00 
PULMONARY WALL 
GROUP A < 6 h 0 0.00 5 14.29 0 0.00 
GROUP B 
24 h 5 14.29 0 0.00 0 0.00 
48 h 5 14.29 0 0.00 0 0.00 
72 h 5 14.29 0 0.00 0 0.00 
GROUP C 
24 h 5 14.29 0 0.00 0 0.00 
48 h 5 14.29 0 0.00 0 0.00 
72 h 5 14.29 0 0.00 0 0.00 
TOTAL 
 
30 85.71 5 14.29 0 0.00 
 
[n = sample size; % = percentage] 
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Table 4.3.3 represents statistical data of thermal denaturation temperature, tensile 
strength and Young’s modulus, performed on samples categorized according to SEM 
classification I-III. 
 
Table 4.3.3 Td, Tensile strength and Young’s Modulus according to SEM 
Categorization I-III 
 
    
 Td TENSILE STRENGTH YOUNG’S MODULUS 
CATEGORY I II III I II III I II III 
AORTIC LEAFLET 
n 5 26 4 5 26 4 5 26 4 
MEAN 70.05 69.88 67.04 3.86 4.04 1.24 13.82 15.39 2.81 
SD 0.87 1.23 0.43 2.34 1.49 0.50 8.66 6.18 1.78 
MINIMUM 69.17 66.61 66.46 1.14 0.70 0.63 5.37 1.94 1.15 
MAXIMUM 71.50 72.94 67.38 6.43 6.78 1.79 26.74 27.74 5.23 
MEDIAN 69.87 69.85 67.16 4.05 4.05 1.26 9.47 14.29 2.43 
PULMONARY LEAFLET 
n 9 12 14 9 12 14 9 12 14 
MEAN 70.17 70.26 69.55 3.45 3.23 2.52 11.28 11.30 7.72 
SD 0.99 0.95 2.09 1.43 0.93 1.78 4.63 3.42 5.82 
MINIMUM 68.28 69.24 66.10 0.55 1.78 0.52 1.83 5.76 1.14 
MAXIMUM 71.57 72.70 72.04 5.02 4.80 5.28 16.89 17.55 17.34 
MEDIAN 70.08 70.17 70.13 3.41 3.09 2.19 11.29 10.82 6.27 
MITRAL LEAFLET 
n 24 10 1 24 10 1 24 10 1 
MEAN 70.66 69.54 68.53 8.02 5.25 0.42 30.81 17.44 1.09 
SD 1.87 1.43  3.75 5.42  12.83 21.32  
MINIMUM 68.48 67.46  1.13 0.45  3.08 0.93  
MAXIMUM 77.39 71.74  15.18 13.98  49.57 49.98  
MEDIAN 70.57 69.65  7.90 2.53  30.65 5.32  
AOTRIC WALL 
n 30 5 - 30 5 - 30 5 - 
MEAN 70.40 69.68  1.30 1.27  4.11 3.16  
SD 0.73 0.49  0.33 0.19  0.98 0.86  
MINIMUM 69.16 69.15  0.69 1.05  2.17 2.12  
MAXIMUM 72.21 70.39  2.03 1.49  6.04 3.97  
MEDIAN 70.40 69.47  1.27 1.32  4.31 3.49  
PULMONARY WALL 
n 30 5 - 30 5 - 30 5 - 
MEAN 71.12 70.57  1.10 1.11  3.60 2.41  
SD 1.55 1.03  0.33 0.34  1.20 0.67  
MINIMUM 68.80 69.43  0.59 0.71  1.75 1.46  
MAXIMUM 77.50 71.95  1.80 1.62  6.26 3.21  
MEDIAN 70.93 70.30  1.09 1.11  3.56 2.43  
          
 
[n=sample size; SD = standard deviation; Td = Thermal denaturation Temperature; - No Values] 
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Table 4.3.4 is a frequency table for H&E results based on SEM categorization I-III. 
 
Table 4.3.4 H&E categorized as normal or autolysis for SEM categorization I-III 
 
 NORMAL AUTOLYSIS 
CATEGORY n n-x % x % 
AORTIC LEAFLET 
I 5 3 60.0 2 40.0 
II 26 22 84.6 4 15.4 
III 4 4 100.0 0 0.0 
Total 35 29 82.9 6 17.1 
PULMONARY LEAFLET 
I 9 6 66.7 3 33.3 
II 12 9 75.0 3 25.0 
III 14 12 85.7 2 14.3 
Total 35 27 77.1 8 22.9 
MITRAL LEAFLET 
I 24 17 70.8 7 29.2 
II 10 10 100.0 0 0.0 
III 1 1 100.0 0 0.0 
Total 35 28 80.0 7 20.0 
AORTIC WALL 
I 30 25 83.3 5 16.7 
II 5 5 100.0 0 0.0 
III 0 0 0.0 0 0.0 
Total 35 30 85.7 5 14.3 
PULMONARY WALL 
I 30 21 70.0 9 30.0 
II 5 5 100.0 0 0.0 
III 0 0 0.0 0 0.0 
Total 35 26 74.3 9 25.7 
 
[n=sample size; x=autolysis; % = percentage] 
 
Table 4.3.5 is a summary of the statistical analysis of inter-group relationships between 
categories I - III.  The valve leaflets (aortic, pulmonary and mitral) were distributed 
throughout the three SEM categories.  The artic wall tissue only met the criteria of 
Category I and II.  Aortic valve leaflets showed a statistically significant difference 
(p<0.05) between category I, II and III for DSC, Tensile strength and Young’s Modulus. 
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4.3.1 Morphology according to SEM category I, II, III 
 
Table 4.3.5 provides a summary of the statistical analysis of the morphological 
classification of harvested valvular homograft tissue according to SEM category I, II and 
III. 
 
Thermal denaturation temperature (Td) showed a statistical significant difference  
(p < 0.05) for aortic valve leaflets between categories I & III as well as between II & III, 
and also between categories I & II of the aorta wall.   
 
Statistical analysis of the tensile strength indicated a significant difference (p < 0.05) in 
categories II & III of the aortic leaflet. 
 
Young’s modulus as calculated from the stress strain curve indicated a statistical 
significant difference (p < 0.05) between categories I & III as well II & III of the aortic 
valve leaflet.  A significant difference (p < 0.05) was also shown between categories I & 
II of the aorta and pulmonary wall respectively.   
 
No statistical significant difference (p < 0.05) was found within the H&E results. 
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Table 4.3.5 Category I vs. II vs. III 
 
    
  
  
  
 A
O
R
TI
C
 L
E
A
FL
E
T 
Td 
TENSILE  
STRENGTH 
YOUNG’S  
MODULUS 
H & E 
Category  p-value Category p-value Category  p-value Category p-value 
I vs. II vs. III p<0.001 I vs. II vs. III 0.008 I vs. II vs. III 0.008 I vs. II vs. III 0.309 
I vs. II 0.780 I vs. II 0.821 I vs. II 0.452 I vs. II - 
I vs. III p<0.001 I vs. III 0.067 I vs. III 0.014 I vs. III - 
II vs. III p<0.001 II vs. III 0.001 II vs. III 0.003 II vs. III - 
P
U
LM
O
N
A
R
Y
 
LE
A
FL
E
T 
I vs. II vs. III 0.445 I vs. II vs. III 0.265 I vs. II vs. III 0.212 I vs. II vs. III 0.607 
I vs. II - I vs. II - I vs. II - I vs. II - 
I vs. III - I vs. III - I vs. III - I vs. III - 
II vs. III - II vs. III - II vs. III - II vs. III - 
M
IT
R
A
L 
LA
E
F
LE
T 
I vs. II vs. III 0.161 I vs. II vs. III 0.083 I vs. II vs. III 0.050 I vs. II vs. III 0.128 
I vs. II - I vs. II - I vs. II - I vs. II - 
I vs. III - I vs. III - I vs. III - I vs. III - 
II vs. III - II vs. III - II vs. III - II vs. III - 
A
O
R
TI
C
 W
A
LL
 
I vs. II vs. III - I vs. II vs. III - I vs. II vs. III - I vs. II vs. III - 
I vs. II 0.042 I vs. II 0.854 I vs. II 0.048 I vs. II 1.000 
I vs. III - I vs. III - I vs. III - I vs. III - 
II vs. III - II vs. III - II vs. III - II vs. III - 
P
U
LM
O
N
A
R
Y
 
W
A
LL
 
I vs. II vs. III - I vs. II vs. III - I vs. II vs. III - I vs. II vs. III - 
I vs. II 0.458 I vs. II 0.943 I vs. II 0.048 I vs. II 0.297 
I vs. III - I vs. III - I vs. III - I vs. III - 
II vs. III - II vs. III - II vs. III - II vs. III - 
 
p<0.05 = statistically significant; p>0.05 = no statistically significant 
(Td= Thermal Denaturation Temperature; IT = Ischaemic Time; SEM = Scanning Electron Microscopy; H&E = Haematoxylin 
and Eosin; h =hours; EM = Equal Mean; - = No Value) 
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4.4 THE QUALITY OF TISSUE HISTOLOGY OF HARVESTED VALVULAR HOMOGRAFTS 
 
The H&E histological stain was used to evaluate changes in cellular composition 
and tissue architecture.  The samples were graded as either being normal or 
autolytic, demonstrating the presence of autolysis. 
 
Table 4.4.1 represents the statistical data of the thermal denaturation 
temperature (Td), tensile strength and Young’s modulus preformed on the 
samples categorized according to H&E classification as either normal or 
autolytic. 
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Table 4.4.1 Td, Tensile strength and Young’s Modulus according to H & E Classification 
(Normal or Autolysis) 
 
 
 
Td TENSILE STRENGTH YOUNG'S MODULUS 
H & E 
CLASSIFICATION 
NORMAL AUTOLYSIS NORMAL AUTOLYSIS NORMAL AUTOLYSIS 
AORTIC LEAFLET 
n 29 6 29 6 29 6 
MEAN 69.58 69.60 3.47 4.79 13.33 15.69 
SD 1.53 1.00 1.69 1.83 7.79 4.12 
MINIMUM 66.46 68.67 0.63 1.85 1.15 9.15 
MAXIMUM 72.94 71.50 6.78 6.49 27.74 20.24 
MEDIAN 69.85 69.37 3.67 5.13 13.19 16.28 
PULMONARY LEAFLET 
n 27 8 27 8 27 8 
MEAN 70.07 69.56 2.74 3.89 9.30 11.75 
SD 1.69 0.63 1.32 1.65 4.98 4.86 
MINIMUM 66.10 68.28 0.52 0.55 1.14 1.83 
MAXIMUM 72.70 70.32 4.80 5.28 17.55 17.34 
MEDIAN 70.34 69.56 2.94 4.69 9.27 11.72 
MITRAL LEAFLET 
n 28 7 28 7 28 7 
MEAN 70.42 69.71 6.62 8.57 25.17 30.05 
SD 1.89 1.44 4.75 3.06 18.54 7.85 
MINIMUM 67.46 68.48 0.42 3.98 0.93 17.94 
MAXIMUM 77.39 72.59 15.18 12.77 49.98 42.00 
MEDIAN 70.57 68.99 6.00 7.69 21.95 28.04 
AORTIC WALL 
n 30 5 30 5 30 5 
MEAN 70.35 69.95 1.30 1.22 3.84 4.80 
SD 0.74 0.75 0.33 0.14 1.02 0.51 
MINIMUM 69.15 69.21 0.69 1.06 2.12 4.28 
MAXIMUM 72.21 71.05 2.03 1.45 6.04 5.53 
MEDIAN 70.35 69.65 1.29 1.21 3.89 4.76 
PULMONARY WALL 
n 26 9 26 9 26 9 
MEAN 71.17 70.67 1.09 1.14 3.33 3.71 
SD 1.60 1.11 0.30 0.41 1.09 1.56 
MINIMUM 68.80 69.47 0.59 0.65 1.46 1.75 
MAXIMUM 77.50 73.15 1.68 1.80 5.88 6.26 
MEDIAN 71.05 70.81 1.08 1.11 3.18 3.60 
       
 
[n=sample size; SD = standard deviation; Td Thermal Denaturation Temperature] 
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Table 4.4.2 SEM categorization I-III according to H & E classification (Normal or 
Autolysis) 
 
 
H&E Classification Category I Category II Category III 
 
n n  % n  % n  % 
AORTIC LEAFLET 
NORMAL 29 3 (10.3) 22 (75.9) 4 (13.8) 
AUTOLYSIS 6 2 (33.3) 4 (66.7) 0 (0.0) 
TOTAL 35 5 (14.3) 26 (74.3) 4 (11.4) 
PULMONARY LEAFLET 
NORMAL 27 6 (22.2) 9 (33.3) 12 (44.4) 
AUTOLYSIS 8 3 (37.5) 3 (37.5) 2 (25.0) 
TOTAL 35 9 (25.7) 12 (34.3) 14 (40.0) 
AORTIC WALL 
NORMAL 30 25 (83.3) 5 (16.7) 0 (0.0) 
AUTOLYSIS 5 5 (100.0) 0 (0.0) 0 (0.0) 
TOTAL 35 30 (85.7) 5 (14.3) 0 (0.0) 
PULMONARY WALL 
NORMAL 26 21 (80.8) 5 (19.2) 0 (0.0) 
AUTOLYSIS 9 9 (100.0) 0 (0.0) 0 (0.0) 
TOTAL 35 30 (85.7) 5 (14.3) 0 (0.0) 
MITRAL LEAFLET 
NORMAL 28 17 (60.7) 10 (35.7) 1 (3.6) 
AUTOLYSIS 7 7 (100.0) 0 (0.0) 0 (0.0) 
TOTAL 35 24 (68.6) 10 (28.6) 1 (2.9) 
 
 
[n=sample size; %= percentages] 
 
4.4.1 THE HISTOLOGY QUALITY OF HARVESTED VALVULAR HOMOGRAFTS 
 
A summary of the histological quality of the harvested valvular homografts is 
displayed in Table 4.4.3.  The only statistically significant differences (p < 0.05) 
were found in the pulmonary leaflets (tensile strength) and aorta wall (young’s 
modulus) normal vs. autolysis.  The other test results did not reveal any statistical 
significant differences (p > 0.05) between normal and autolytic tissue. 
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Table 4.4.3 Normal vs. Autolysis 
 
   
 Td 
           TENSILE  
            STRENGTH 
         YOUNG’S  
          MODULUS 
SEM 
 IT           p-value IT        p-value            IT          p-value IT p-value 
A
O
R
TI
C
 
LE
A
FL
E
T Normal 
vs. 
Autolysis 
0.969 
Normal vs. 
Autolysis 
0.095 
Normal vs. 
Autolysis 
0.381 
Normal vs. 
Autolysis 
0.309 
P
U
LM
O
N
A
R
Y
 
LE
A
FL
E
T Normal 
vs. 
Autolysis 
0.418 
Normal vs. 
Autolysis 
0.049 
Normal vs. 
Autolysis 
0.239 
Normal vs. 
Autolysis 
0.607 
M
IT
R
A
L 
LE
A
FL
E
T Normal 
vs. 
Autolysis 
0.363 
Normal vs. 
Autolysis 
0.313 
Normal vs. 
Autolysis 
0.592 
Normal vs. 
Autolysis 
0.128 
A
O
R
TI
C
  
LE
A
FL
E
T Normal 
vs. 
Autolysis 
0.263 
Normal vs. 
Autolysis 
0.599 
Normal vs. 
Autolysis 
0.043 
Normal vs. 
Autolysis 
1.000 
P
U
LM
O
N
A
R
Y
 
LE
A
FL
E
T Normal 
vs. 
Autolysis 
0.394 
Normal vs. 
Autolysis 
0.655 
Normal vs. 
Autolysis 
0.624 
Normal vs. 
Autolysis 
0.297 
 
p<0.05 = statistically significant; p>0.05 = not statistically significant 
(Td = Thermal Denaturation Temperature; SEM = Scanning Electron Microscopy) 
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5.1 INTRODUCTION 
 
Despite the establishment of homograft banks through the development of 
cryopreservation, demand for homografts exceeds the supply.  The shortage may in 
part be due to the harvesting protocols popularised by O’Brien et al., (1988) and Livi 
et al., (1987) who promoted a harvest time of less than 24 hours (O’Brien et al., 1988; 
Livi et al., 1987).  The time limit of 24 hours was thought necessary to ensure cellular 
viability, particularly of endothelial cells and fibroblasts, which in turn was thought to 
influence long-term valve stability (Angell et al., 1989; O’Brien et al., 1995).  
However, other series demonstrated that acceptable results could be achieved 
with post mortem harvest times of up to 60 hours (Armiger 1995, Messier et al., 1992, 
Lu et al., 1998). 
 
Prior to 1995, harvested homograft valves were stored in an albumin and antibiotic 
solution for periods of up to 90 hours (Langley et al., 1996).  The incidence of re-
operation for aortic valve homograft failure in the aortic position at 10 years was 
12.1% (Langley et al., 1996).   
 
The Homovital homograft concept was introduced by Yacoub and co-workers in 
1995, (Yacoub et al., 1995).  This series implanted homografts with storage times of 3 
hours to 60 days.  Although most of these implants had storage times of less than 48 
hours, the authors did  not comment on the implants with very long storage times.  
Other authors (Yankah and Hertzer, 1987) have shown that only 24% of the 
endothelium survives a storage time at room temperature of 2 hours, with complete 
destruction of the endothelium noted after storage times between 24 hours and 48 
CHAPTER 5 
DISCUSSION 
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hours.  It appears that the anticipated absence of endothelium in homografts with 
storage times greater than 48 hours would contradict the claim that the grafts 
implanted in the Yacoub series (Yacoub et al., 1995) were in fact Homovital by 
definintion. 
 
O’Brien et al., 1987 stated that optimal viability of a homograft could only be 
ensured if harvest times were not longer than 24 hours and moreover, that this time 
period should ideally be less than 6 hours.  Furthermore, the homograft should be 
cryopreserved within 4 days of harvesting (O’Brien et al., 1987; Langley et al., 1996).  
Post mortem autolysis of human tissue begins approximately 4 minutes after death 
but these changes are not macroscopically detectable for several days (Vass, 
2001).  This direct relationship between progressive autolysis and ischaemic time, 
dictates the acceptable limit of ischaemic time from death to cryopreservation 
(Moriyama, Utoh, Hagiwara, Kunitomo, Katsuhide and Kitamura, 2001).   
Importantly, O’Brien et al., has shown that homograft degeneration is delayed if it 
contains viable fibroblasts and endothelial cells at the time of implantation (O’Brien 
et al., 1987). 
 
Notwithstanding the limitation on ischaemic/harvesting time, many homograft 
banks prolong the ischaemic time.  The ischaemic time is prolonged because of the 
pre-cryopreservation processes to which the valves are subjected, namely 
dissection, incubation and sterilisation.  This prolongation of ischaemic time can be 
as long as 96 hours (Gall et al., 1998). 
 
The insistence that harvest time must be limited to 24 hours is refuted in the above 
publications.  However, this 24 hour limitation might still apply, if homograft tissue in 
the cadaver was compromised by any adverse event. 
 
Another important aspect of this discussion is that harvest time of less than 24 hours 
does not necessarily guarantee viable fibroblasts and endothelial cells at 
implantation.  Therefore, it appears that Ischaemic time is not the only factor that 
influences homograft viability.  Although numerous studies have demonstrated that 
cryopreservation maintains tissue integrity, there is evidence that the number of 
C h a p t e r  5  –  D i s c u s s i o n   P a g e  | 88 
 
viable cells decline during the pre-implantation processes (Gall et al., 1998).  The 
likely reasons for this decline are possibly related to the handling, freezing and 
thawing processes used (Mirabet, Carda, Solves, Novella-Maestre, Carbonell-
Uberos, Caffarena, Hornero, Montero and Roig, 2008). 
 
On the other hand, importantly, Wheatley and co-workers have raised important 
questions about the presence of excessive viable endothelium cells during 
implantation.  In their study, large numbers of viable cells (fresh homografts) lead to 
immune reactions, which accelerate the calcification of these valves (Wheatley 
and McGregor, 1977). 
 
The question might arise: how many viable cells are necessary during implantation 
to ensure optimal stability and how many endothelium cells should be lost before 
the immune response is blunted? 
 
Is time the only factor promoting tissue autolysis?  Numerous other factors contribute 
to the development of tissue autolysis.  The circumstances surrounding death, post-
mortem temperature changes (tempo of cooling down), body mass index (BMI) 
etc., and are all factors that may influence the tempo of degenerative processes 
as is well described by (Vass, 2001). 
 
A study was therefore designed to establish the impact on tissue strength for periods 
up to 72 hours on sheep homografts. The homografts were prepared in two groups, 
where the one group was allowed to remain at warmer temperatures and the other 
group was cooled intentionally. The impact of ischaemic time under these 
conditions was evaluated by documenting the histological appearance as well as 
the condition of the endothelium using SEM. 
 
These groups were then evaluated as regards tissue strength using objective 
measurements (Tensile strength and thermal denaturation temperatures). 
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5.2 Results: 
 
To determine the impact of ischaemic time and temperature, the study 
focused on three groups: (a) the control group (Group A) which contained 
homograft valves subjected to < 6 hours ischaemic time, stored at 4ºC; (b) the 
cold ischaemic group (Group B) subjected to 24 hours, 48 hours and 72 hours 
ischaemic times, stored at 4ºC, after which the valves were processed and 
cryopreserved; (c) the warm ischaemic group (Group C) subjected to 24 
hours, 48 hours and 72 hours ischaemic times, stored for 6 hours at room 
temperature (23ºC), followed by 18 hours, 42 hours and 66 hours at 4ºC, after 
which the valves were processed and cryopreserved.  The actual 
temperatures reached are reported in figure 4.2.1. 
 
To achieve the above-mentioned goals, the following tests were selected to 
evaluate tissue integrity and quality in the different subsets.  
 
•  Tissue strength: 
- Thermal denaturation temperature, 
- Tensile strength 
- Young’s Modulus 
Morphology 
- Scanning Electron Microscopy (SEM) 
- H&E histological stain 
 
5.3 Group A (Control group) 
 
SEM demonstrated endothelium on all aortic and pulmonary valve structures, 
although some of the structures showed signs of endothelium damage.  The 
aorta and pulmonary walls lost nearly all their endothelium, but the basement 
membrane was still clearly visible. Morphologically, however, it was clear that 
the degenerative processes began sooner in the aorta than in the pulmonary 
valve scaffolding (SEM evaluation). 
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H&E colouring showed no autolysis, and all the samples were classified as 
normal. 
 
DSC indicated little variation as well as a constant denaturation temperature. 
 
Tensile strength was very difficult to determine as a result of the small size of 
the valvular samples.  This caused sample slippage but the same problem was 
encountered by Patwardhan when evaluating the stress-strain curves (a 
common problem when testing small biological samples which influence the 
ability to grip the sample).  As a result, the valve tensile strength could only be 
determined in one direction (uniaxial), although both directions (biaxial) 
would be preferred. The former method, however, produces acceptable 
results (Patwardhan and Vaideeswar, 2004). 
 
The results showed a wide variation in the tensile strength.  A larger number of 
samples were used, but the variation remained a problem unique to this test. 
 
Young’s modulus was performed as an alternative test to determine whether 
more reliable results could be obtained with regard to tensile strength.  Since 
Young’s modulus is inferred from the tensile strength graph, the “slippage” 
however also resulted in wide variations. 
 
There was no statistically significant difference between the respective 
strengths of the aortic and pulmonary valve structures and the aorta and 
pulmonary walls. 
 
5.4 Ischaemic time 
 
5.4.1 Group B 
 
Group B constituted the “cold ischaemic” group.  
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Fifteen carcasses were divided into three groups of five each and 
exposed to 24 hours, 48 hours and 72 hours ischaemic time respectively.  
During the ischaemic time, the carcasses were kept in a refrigerator at 
4ºC.  It took the carcasses 24 hours to reach 4˚C core temperature.  
Afterwards, they were processed, sterilised and frozen.  The valves were 
thawed and then underwent a battery of tests. 
 
SEM demonstrated a reduction in endothelium over time.  The majority 
of the aortic valve leaflets fell in Category II (scattered endothelial cells 
and intact basal membrane), 24 h (95.8%), 48 h (80%) and 72 h (73.9%).  
The pulmonary valve leaflets showed that at 24 h (50%) in category III, 
48 h (60.9%) in Category II and 72 h (40.9%) in Category II and (40.9%) in 
Category III).  Therefore, both the aortic and pulmonary valves showed 
endothelial cells up to 72 h. 
 
H&E colouring showed no visible histological signs of early autolysis after 
72 h. 
 
No statistically significant reduction in tensile strength could be 
demonstrated between the three ischaemic time intervals.  Tensile 
strength was not lower than that of the control group in any of the 
groups. 
 
DSC confirmed the results with regard to tensile strength.  Once again, 
the tissue strength remained constant with respect to the control group 
and group B despite the prolonged ischaemic times and 
cryopreservation techniques. 
  
5.4.2 Group C 
 
In group C (warm ischaemic group), 15 carcasses were stored, first at 
room temperature (23˚C) for 6 hours, and afterwards at 4ºC.  The 
carcasses were also divided into three groups of five each, involving 24 
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hours, 48 hours and 72 hours ischaemic time respectively.  After the 
groups were subjected to the applicable ischaemic times and 
cryopreservation techniques, samples of valve and wall tissue 
underwent five tests. 
 
SEM indicated that a progressive decrease in endothelium coverage 
and viability took place with a concurrent increase in ischaemic time.  
Although endothelium declined significantly, some valves had an 
endothelium presence after 72 hours worth mentioning.  The aortic 
valves leaflets after 24 h (84%) fell in Category II (scattered endothelial 
cells and intact basal membrane), after 48 h (100%) in Category I (Basal 
membrane and endothelial cells completely absent), and 72 h (56%) in 
category II (scattered endothelial cells and intact basal membrane).  
The pulmonary valve leaflets showed that at 24 h and 48 h (68% and 
60%) respectively fell in Category I, and 72 h (40%) in Category II and 
(36%) in Category I. 
 
H&E colouring showed visible signs of autolysis in the .aortic valve 
leaflets (20%), pulmonary valve leaflets (60%), mitral valve leaflets (40%) 
and pulmonary wall (80%) of the 48 h group.  Of the 72 h group (100%) 
of the valve leaflets and artery wall samples showed the presence of 
autolysis.  These results were not unexpected since the tissue had 
already shown macroscopic signs of degenerative change.  The tissue 
showed changes in colour, accompanied by an unpleasant odour. 
 
No statistically significant reduction in tensile strength could be 
demonstrated between the three groups and there were no 
differences between the three ischaemic time intervals.  Tensile strength 
was not lower than that of the control group, and comparable to the 
results obtained from the cold ischaemic group. 
 
Once again, the results of the DSC analysis confirmed the 
measurements/conclusions of the tensile strength tests.  The strength of 
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the tissue did not decrease as a result of prolonged ischaemic times, 
and apparently, even at higher temperatures, tissue strength was 
retained.  Even in the presence of autolysis, the thermal denaturation 
temperature results were not lower than that of the control group (Td 
mean = 69.60 °C for group C (autolytic samples) vs. Td mean = 66.95 °C 
for Group A (control group). 
 
5.5 SEM Classification 
  
In order to analyse tissue using the retention of endothelium as a benchmark 
for possible viability of tissue and its impact on tissue strength, samples were 
divided into three groups, irrespective of the ischaemic time or temperature 
that it was exposed to. 
No statistically significant differences were found between the three groups 
with regard to DSC, tensile strength, Young’s modulus and H&E.  
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6.1 GENERAL CONCLUSION 
The fresh tissue in group A showed morphologically good confluent endothelium 
coverage of the valve scaffolding, although the aortic and pulmonary walls lost 
a great deal of their endothelium.  No autolysis was observed and a bench mark 
was set for tissue strength using Tensile strength, Young’s modules and thermal 
denaturation temperature (Td) tests. 
Compared to the baseline (Group A), the cold ischaemic group (Group B) 
showed no increased signs of autolysis up to 72 hours. The endothelium coverage 
decreased with increased ischaemic time and in the 72 hour group 91.3% of 
aortic and 59.1% of pulmonary valvular tissue had no or incomplete endothelium 
cover. 
No reduction of tensile strength or in Young’s Modules could be demonstrated 
and thermal denaturation temperature showed no decrease in strength up to 72 
hours compared to the control group. 
These results, surprisingly, hold true for Group C (warm ischaemic time).  In Group 
C some valves demonstrated early autolysis, but still retained tissue strength as 
demonstrated by tensile strength and thermal denaturation temperature 
evaluation.  
This study demonstrates that tensile strength as well as basic morphology (H&E 
stain) of valvular tissue is retained up to 72 hours. 
 
There is a reduction of endothelium cover over time, but this does not have a 
significant impact on the physical properties of the homograft tissue according to 
CHAPTER 6 
CONCLUSION 
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the in vitro tests we applied.  It therefore remains to be demonstrated in an in vivo 
model, what, if any impact, ischaemic time has on the functioning and 
degeneration of homografts. 
 
We could not demonstrate a reliable relationship between pulmonary and aortic 
wall data that would provide predictive methods. 
 
Cryopreservation and tissue processing had no deleterious effect on tissue 
strength.  
  
6.2 FUTURE RECOMMENDATIONS 
In vivo studies of animals are proposed to further investigate the outcomes of the 
various ischaemic groups in a sheep model.  
 
Degeneration of homografts should be studied in an attempt to qualify and 
quantify underlying mechanisms. 
 
An attempt should be made to explain the biological impact or lack thereof, of 
increased ischaemic time on in vivo behaviour of homografts. 
 
Host tissue interaction might be important in understanding the final outcome of 
homografts in vivo. 
 
6.3 LIMITATIONS 
 The study was limited by: 
•  The size of tissue samples (valvular leaflets) caused technical difficulties 
especially when performing tensile strenght testing 
•  Analysis requires a high level of skills (Scanning Electron Microscopy) 
•  Financial constraints limited sample pool 
R e f e r e n c e s   P a g e  | 96 
 
 
 
 
 
 
 
 
 
Akhyari, P., Fedak, P.W.M., Weisel, R.D., Lee, T.Y., Verma, S., Mickle, D.A. & Li, R.K. 2002.  
Mechanical Stretch Regimen Enhances the Formation of Bioengineered 
Autologous Cardiac Muscle Grafts.  Circulation 106(I): 137-142. 
 
Ali, M.L., Kumar, S.O., Bjornstad, K. & Duran, C.M. 1996.  The sheep as an animal model for 
heart valve research.  Cardiovascular Surg 4(4): 543-549. 
 
Allen, M.D., Shoji, Y., Fujimura, Y., Gordon, D., Thomas, R., Brockbank, K.G. & Disteche, C.M. 
1991.  Growth and cell viability of aortic versus pulmonic homografts in the 
systemic circulation.  Circulation 84: SIII 94-99. 
 
Anastasiadis, K., Kambouroglou, D. & Spanos, P. 2004.  The use of valve homografts and 
autografts in adult cardiac surgery.  Hellenic J Cardiol 45: 36-41. 
 
Angell, W.W., Iben, A.B. & Shumway, N.E. 1968.  Fresh aortic homografts for multiple valve 
replacement.  Arch Surg 97: 826-830. 
 
Angell, W.W., Oury, J.H., Lamberti, J.J. & Koziol, J. 1989.  Durability of the viable aortic 
allograft.  J Thorac Cardiovasc 98: 48-56. 
 
Arminger, L.C. 1995.  Viability studies of human valves prepared for use as allografts.  Ann 
Thorac Surg 60: S118-121. 
 
 
 
 
REFERENCES 
R e f e r e n c e s   P a g e  | 97 
 
Barili, F., Dainese, L., Cheema, F.H., Dell’Antonio, G.,Topkara, V.K., Rossoni, G., Guarino, A., 
Micheli, B., Doglioni, C., Biglioli, P. & Polvani, G. 2007.  Rates of Cycling Cells in 
Cryopreserved Valvular Homograft: A Preliminary Study.  Artificial Organs 31(2): 
152-154. 
 
Barret-Boyes, B.G. 1965.  A method for preparing and inserting a homograft aortic valve.  
Br J Surg 52: 847-856. 
 
Barret-Boyes, B.G., Roche, A.H. & Whitlock, R.M.L. 1977.  Six year review of the results of 
freehand aortic valve replacement using an antibiotic sterilized homograft 
valve.  Circulation 55: 353-361. 
 
Barret-Boyes, B.S., Roche, A.H.G., Subramanian, R., Pemberton, J.R. & Whitlock, R.M.L. 1987.  
Long-term follow-up of patients with the antibiotic sterilized aortic homograft 
valve inserted freehand in the aortic position.  Circulation 75: 768-777. 
 
Barrett-Boyes, B. 1987. 25 years clinical experience of allograft surgery - a time for 
reflection 1962 – 1987.  Yankah, A.C., Hetzer, R., Miller, D.C., Ross, D.N., 
Somervill, J. & Yacoub, M.H. Cardiac Valve Allografts. Springer: New York. pp. 
347 – 358. 
 
Beach, P.M., Bowman, F.O., Kaiser, G.A., Parodi, E. & Malm, J.R. 1972.  Aortic valve 
replacement with frozen irradiated homografts – long-term evaluation.  
Circulation 45&46: S29-35. 
 
Bechtel, J.F., Bartlets, C., Schmidtke, C., Skibba, W., Müller-Steinhardt, M., Klüter, H. & 
Sievers, H. 2001.  Does histocompatability affect homograft valve function 
after the Ross procedure?  Circulation 104 (Suppl I): I25-I28. 
 
Crescenzo, D.G., Hilbert, S.L., Barrik, M.K., Corcoran, P.C., St. Louis, J.D., Messier, R.H., 
Ferrans, V.J., Wallace, R.B. & Hopkins, R.A. 1992.  Donor heart valves: electron 
microscopic and morphometric assessment of cellular injury induced by warm 
ischemia.  J Thorac Cardiovasc Surg 103: 253-258. 
 
R e f e r e n c e s   P a g e  | 98 
 
Feng, X.J., van Hove, C.E., Mohan, R., Walter, P.J. & Herman, A.G. 1993.  Effects of different 
antibiotics on the endothelium of the porcine aortic valve.  J. Heart Valve Dis 
2(6): 694 – 704. 
 
Fontan, F., Choussat, A., Deville, C., Doutremepuich, C., Coupilaud, J. & Vosa, C. 1984.  
Aortic valve homografts in the surgical treatment of complex cardiac 
malformations.  J Thorac Cardiovasc Surg 87: 649-657. 
 
Frank, M.W., Mavroudis, C., Backer, C.L. & Rocchini, A.P. 1998.  Repair of mitral valve and 
subaortic mycotic aneurysm in a child with endocarditis.  Ann.  Thorac.  Surg 
65: 1788-1790. 
 
Gall, K.L., Smith, S., Willmette, C.A. & O’Brien, M.F. 1998.  Allograft heart valve viability and 
valve processing variables.  Ann Thorac Surg 65: 1032-1038. 
 
Gall, K.L., Smith, S., Willmette, C.A., Wong, M. & O’Brien, M. 1995.  Allograft heart valve 
sterilization a six year in depth analysis of the twenty five year experience with 
low dose antibiotics.  J Thorac Cardiovasc Surg 110: 680-687. 
 
Gamble,M. 2008. The hematoxylins and eosin, in Bancroft, J.D. & Gamble, M.  Theory and 
practice of histological techniques.  Churchill Livingstone Elsevier: Philadelphia. 
pp. 121-134. 
 
Goffin, Y., Grandmougin, D. & Van Hoeck, B. 1996.  Banking cryopreserved heart valves in 
Europe: assessment of a 5-year operation in an international tissue bank in 
Brussels.  Eur J Cardio-thorac Surg 10: 505-512. 
 
Goffin, Y.A.H., De Gouveia, R.H., Szombathelyi, T., Toussaint, J.M. & Gruys, E. 1997.  
Morphological study of homograft valves before and after cryopreservation 
and after short-term implantation in patients.  Cardiovasc Pathol 6(1): 35-42. 
 
Gonzalez_Lavin, L., Spotnitz, A.J., Mackenzie, J.W., Gu, J., Gadi, I.K., Gullo, J., Boyd, C. & 
Graf, D. 1990.  Homograft valve durability: Host or donor influence?  Heart and 
Vessels 5: 102 – 106. 
R e f e r e n c e s   P a g e  | 99 
 
Groczynski, A., Trenker, M., Anisimowicz, L., Gutkowski, R., Drapella, A., Kwiatkowska, E. & 
Dobke, M. 1982.  Biomechanics of the pulmonary autograft valve in the aortic 
position.  Thorax 37: 535-539. 
 
Hammon, J.W., O’Sullivan, M.J., Oury, J. & Fosburg, R.G. 1974.  Allograft cardiac valves.  A 
view through the scanning electron microscope.  J Thorac Cardiovasc Surg 
68: 352 – 360.   
 
Henssge, C., Knight, B., Krompecher, T., Madea, B. & Nokes, L. 2007.  The estimation of the 
time since death.  Forensic Science International 165(2): 182-184. 
 
Höhne, G.W.H., Hemminger, W.F. & Flammersheim, H.-J. 2003.  Differential Scanning 
Calorimetry: An Introduction for practitioners.  Springer: New York. p.1 
 
Ionescu, M.I., Wooler, G.H., Whitaker, W., Smith, D.R., Taylor, S.H. & Hargreaves, M.D. 1968.  
Heart valve replacement with reinforced aortic heterografts.  J Thorac 
Cardiovasc Surg 56: 333-350. 
 
Julien, M., Létouneau, D.R., Marois, Y., Cardou, A., King, M.W., Guidoin, R., Chachra, D. & 
Lee, J.M. 1997.  Shelf-life of bioprosthetic heart valves: a structural and 
mechanical study.  Biomaterials 18: 605-612. 
 
Kadner, A., Chen, R.H., Mitchell, R.N. & Adams, D.H. 2001.  Homograft cross matching is 
unnecessary due to the absence of blood group antigens.  Ann Thorac Surg 
71(Suppl): S349-S352.  
 
Kadoba, K., Arminger, L., Sawatari, K. & Jonas, R.A. 1991.  Influence of time from donor 
death to graft harvest on conduit function of cryopreserved aortic allografts in 
lambs.  Circulation 84: S100-111. 
 
Kirklin, J.K., Smith, D., Novick, W., Naftel, D.C., Kirklin, J.W., Pacifico, A.D., Nanda, N.C., 
Helmcke, F.R. & Bourge, R.C. 1993.  Long-term function of cryopreserved aortic 
homografts.  A ten-year study.  J Thorac Cardiovasc Surg 106(1): 154-165. 
R e f e r e n c e s   P a g e  | 100 
 
Kirklin, J.W., Blacstone, E.H., Maehara, T., Pacifico, A.D., Kirklin, J.K., Pollock, S. & Stewart, 
R.W. 1987.  Intermediate-term fate of cryopreserved allograft and xenograft 
valved conduits.  Ann Thorac Surg 44: 598-606. 
 
Koolbergen, D.R., Hazekamp, M.G., de Heer, E., van Hoorn, F., Huysmans, H.A., Bruijn, J.A. 
& Dion, R.A.E. 2002.  Structural degeneration of pulmonary homografts used as 
aortic valve substitute underlines early graft failure.  European Journal of 
Cardio-thoracic Surgery 22: 802-807. 
 
Krs, O., Burkert, J., Slizova, D., Kobylka, P. & Spatenka, J. 2006.  Allograft semilunar cardiac 
valves processing and cryopreservation –morphology in scanning electron 
microscope.  Cell and tissue banking 7: 167-173. 
 
Kumar, V., Abbas, A.K., Fausto, N., Robbins, S.L. & Cotran, R.S. 2005. Robbins and Cotran 
pathological basis of disease. Elsevier Saunders: Michigan. pp.1 – 42. 
 
Lacour-Gayet, F., Sauer, H., Ntalakoura, K., Müller, A., Razek, V., Weil, J. & Haun, C. 2004.  
Ross-Konno procedure in neonates:  report of three patients.  Ann  Thorac Surg 
77: 2223-2225. 
 
Lam, C.R., Aram, H.H. & Mennell, E.R. 1952.  An experimental study of aortic valve 
homografts.  Surg Gynocol Obstet 94: 129-131. 
 
Langley, S.M., Livesey, S.A., Tsang, V.T., Barron, D.J., Lamb, R.K., Ross, J.K. & Monro, J.L. 
1996.  Long-term results of valve replacement using antibiotic-sterilised 
homografts in the aortic position.  Eur J Cardio-thorac Surg 10: 1097-1106. 
 
Livi, U., Abdulla, A.K., Parker, R., Olsen, E.J. & Ross, D.N. 1987.  Viability and morphology of 
aortic and pulmonary homografts, a comparative study.  J Thorac Cardiovasc 
Surg 93: 755-760. 
 
Lovekamp, J. & Vyavahare, N. 2001.  Periodate-mediated glycosaminoglycan stabilization 
in bioprosthetic heart valves.  Journal of Biomedical Materials Research 56(4): 
478-486. 
R e f e r e n c e s   P a g e  | 101 
 
Lu, J.H., Chang, Y., Hsu, W.H., Hwang, B., Chong, C., Wu, C. Yang, P. & Hsing-Wen, H. 1998.  
Metabolic detriment in donor heart valves induced by ischemia and 
cryopreservation.  Ann Thorac Surg 66: 1864-1865. 
 
Ma, C.Y. & Harwalkar, V.R. 1991.  Thermal analysis of food proteins.  Advances in food and 
nutrition research 35: 317-366. 
 
McGiffin, D.C., O’Brien, M.F., Stafford, E.G., Gardner, M.A & Pohlner, P.G. 1988.  Long-term 
results of the viable cryopreserved allograft aortic valve: continuing evidence 
for superior valve durability.  J Cardiac Surg 3: S289-296. 
 
McNally, R.T. & Brockbank, K.G. 1992.  Issues surrounding the preservation of viable 
allograft heart valves.  J Med Eng Technol 16(1): 34-38. 
 
Mermet, B., Buch, W. & Angell, W.W. 1970.  Viable heart valve graft: preservation in the 
frozen state.  Surg Forum 21:156-157. 
 
Messier, R.H., Domkowski, P.W., Aly, H.M., Abd-Elfattah, A.S. Crescenzo, D.G., Wallace, B. & 
Hopkins, R.A. 1992.  High energy phosphate depletion in leaflet matrix cells 
during processing of cryopreserved cardiac valves.  J Surg Res 52: 483-488. 
 
Mirabet, V., Carda, C., Solves, P., Novella-Maestre, E., Carbonell-Uberos, F., Caffarena, 
J.M., Hornero,F., Montero, J.A. & Roig, R.J. 2008.  Long term storage in liquid 
nitrogen does not affect cell viability in cardiac valve allografts.  J.Cryobiol 57: 
113-121. 
 
Mitchell, R.N., Jonas, R.A. & Schoen, F.J. 1995.  Structure-function correlations in 
cryopreserved allograft cardiac valves.  Ann Thorac Surg 60: S108-113. 
 
Moriyama, S., Utoh, J. Murai, Y., Hagiwara, S., Kunitomo, R., Katsuhide, N. & Kitamura, N. 
2001.  Functional metabolic, and histological changes of vascular tissue after 
warm ischemia.  Ann Thorac Cardiovasc Surg 7(3): 143-149. 
 
R e f e r e n c e s   P a g e  | 102 
 
Murray, G. 1956.  Homologous aortic valve segment transplants as surgical treatment for 
aortic and mitral insufficiency.  Angiology 7: 446-451. 
 
O’Brien, M.F., Johnston, N., Stafford, G., Gardner, M., Pohlner, P., McGiffin, D., Brosnan, A. & 
Duffy, P. 1988.  A study of the cells in the explanted viable cryopreserved 
allograft valve.  J Card Surg 3: S279-287. 
 
O’Brien, M.F., Stafford, E.G., Gardner, M.A.H., Pohlner, P. & McGiffin, D. 1987.  A 
comparison of aortic valve replacement with viable cryopreserved and fresh 
allograft valves, with a note on chromosomal studies.  J Thorac Cardiovasc 
Surg 94: 812-823. 
 
O’Brien, M.F., Stafford, G.E., Gardner, M.A.H. 1995.  Allograft aortic valve replacement: 
long-term follow-up.  Ann Thorac Surg 60: S65-70. 
 
Páral, J., Ferko, A., Mĕřička, P.,Slizova D., Nozicka, J., Chovanec, V. & Raupach, J. 2000.  
Contribution to preservation of venous grafts.  Rozhl Chir 79: 244 – 249. 
 
Patwardhan, A.M. & Vaideeswar, P. 2004.  Stress strain characteristics of glutaraldehyde 
treated porcine aortic valve tissue following ethanol treatment.  IJTCVS 20: 67-
71. 
 
Pompilio, G., Polvani, G.L., Antona, C.Rossoni, G., Guarino, A., Porqueddu, M., Buche, M., 
Biglioli, P. & Sala, A. 1996.  Retention of endothelium-dependent properties in 
human mammary artery following cryopreservation.  Ann Thorac Surg 61: 667-
673. 
 
Pompilio, G., Polvani, G.L., Rossoni, G., Porqueddu, M., Berti, F., Barajon, I.,Petruccoili, M.G., 
Guarino, A., Aguggini, G., Biglioli,P., & Sala,A. 1997.  Effects of warm ischemia 
on valve endothelium.  Ann Thorac Surg 63: 657-662. 
 
Pukacki, K., Jankowski, T., Gabriel, M., Oszkinis, G., Krasinski, Z. & Zapalski, S. 2000.  The 
mechanical properties of fresh and cryopreserved arterial homografts.  Eur J 
Endovasc Surg 20: 21-24. 
R e f e r e n c e s   P a g e  | 103 
 
Ross, D.N. 1962.  Homograft replacement of the aortic valve.  Lancet 2: 447,487. 
 
Ruegg, M., Moor, U. & Blanc, B. 1977.  A calorimetric study of the thermal denaturation of 
whey proteins in simulated milk ultrafiltrate.  Journal of dairy research 44(3): 
509-520. 
 
Sasaki, N. & Odajima, S. 1996.  Stress-Strain curve and young’s modulus of a collagen 
molecule as determined by the x-ray diffraction technique.  Journal of 
Biomechanics 29(5): 655-658. 
 
Savage, P., Jones, C.D., Thompson, D. & Ross, D.N. 1972.  The fate of aortic valve 
homografts: an experimental study.  Br J Surg 59: 231-234. 
 
St Louis, J., Corcoran, P., Rajan, S., Conte J., Wolfinbarger L., Hu J., Wang Y.N., Hilbert S., 
Analouei A. and Hopkins R.A. 1991.  Characterization of effects of warm 
ischemia following harvesting of allograft cardiac valves.  European Journal of 
Cardiothoracic Surgery 5: 458-465. 
 
Stelzer, P. & Elkins, R.C. 1989.  Homograft valves and conduits: applications in cardiac 
surgery.  Curr Probl Surg 26(6): 381-452. 
 
Stinson, E.B., Angell, W.W. & Shumway, N.E. 1968.  Triple valve replacement with aortic 
homografts.  JAMA 204: 67-69. 
  
The Principles of ICH GCP.  Available from: http://www.ncehr-
cnerh.org/english/gcp/principles.html Accessed: [04 March 2007]. 
 
Thubrikar, M.J., Deck, J.D., Aouad, J. & Nolan, S.P. 1983.  Role of mechanical stress in 
calcification of aortic bio prosthetic valves.  The Journal of Thoracic and 
Cardiovascular Surgery 86: 115-125. 
 
Van der Kamp, A.W. & Nauta, J. 1979.  Fibroblast function and the maintenance of the 
aortic-valve matrix.  Cardiovasc Res 13(3): 167-172. 
 
R e f e r e n c e s   P a g e  | 104 
 
Vass, A.A. 2001.  Beyond the grave-understanding human decomposition.  Microbiology 
Today 28: 190-192. 
 
Verghese, S., Padmaja, P., Sindhu, B., Elizabeth, S.J., Lesley, K.M. & Cherian, K.M. 2004.  
Homograft valve bank:  Our experience in valve banking.  Indian Heart J 56: 
299-306. 
 
Wain, W.H., Pearce, H.M., Riddell, R.W. & Ross, D.N. 1977.  A re-evaluation of antibiotic 
sterilization of heart valve allografts.  Thorax 32(6): 740-742. 
 
Wallace, R.B., Rastelli, G.C., Ongley, P.A., Titus, J.C. & McGoon, D.C. 1969.  Complete 
repair of truncus arteriosus defects.  J Thorac Cardiovas Surg 57: 95-107. 
 
West, R. & Burr, G. 2002.  Why families deny consent to organ donation.  Aust Crit Care 
15(1): 27-32. 
 
Wheatley, D.J. & McGregor, C.G.A. 1977.  Influence of viability on canine allograft heart 
valve structure and function.  Cardiovascular Research 11(3): 223-230. 
 
World Medical Association.  Declaration of Helsinki [online].  2002.  Available from: 
http://www.faseb.org/aevo/helsinki.htm Accessed: [6 October 2007]. 
 
Yacoub, M. & Kittle, C.F. 1970.  Sterilization of valve homografts by antibiotic solutions.  
Circulation 41: SII29-31. 
 
Yacoub, M., Rasmi, N.R. & Sundt, T.M., Lund, O., Boyland, E., Radley-Smith, R.,Khaghani,A. 
& Mitchell, A. 1995.  Fourteen-year experience with homovital homografts for 
aortic valve replacement.  J Thorac Cardiovasc Surg 110: 186-194. 
 
Yankah, A.C. & Hertzer, R. 1987.  Procurement and viability of cardiac valve allografts, in: 
Yankah, A.C. Cardiac valve allografts 1962-1987. Springer-Report: New York 
pp. 23-26. 
 
 
A p p e n d i x  A   P a g e  | 105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Appendix A 
A p p e n d i x  A   P a g e  | 106 
 
 
A p p e n d i x  A   P a g e  | 107 
 
 
 
